10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-21-033243.txt : 20210209 0001193125-21-033243.hdr.sgml : 20210209 20210209063545 ACCESSION NUMBER: 0001193125-21-033243 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210209 DATE AS OF CHANGE: 20210209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Benitec Biopharma Inc. CENTRAL INDEX KEY: 0001808898 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39267 FILM NUMBER: 21603880 BUSINESS ADDRESS: STREET 1: LEVEL 14, 114 WILLIAM ST CITY: MELBOURNE, VIC STATE: C3 ZIP: 3000 BUSINESS PHONE: 61(0)3 8692-7222 MAIL ADDRESS: STREET 1: LEVEL 14, 114 WILLIAM ST CITY: MELBOURNE, VIC STATE: C3 ZIP: 3000 10-Q 1 d125513d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-39267

BENITEC BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Delaware

84-462-0206

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)


3940 Trust Way, Hayward, California 94545
(Address of principal executive offices & zip code)

(510) 780-0819

(Registrant’s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001

BNTC

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ or No ☒

We had 4,540,469 shares of our common stock outstanding as of the close of business on February 4, 2021.

BENITEC BIOPHARMA INC.

INDEX TO FORM 10-Q


SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS			2

PART I-FINANCIAL INFORMATION			1

ITEM 1. Financial Statements (unaudited)

Consolidated Balance Sheets as of December 31, 2020 (Unaudited) and June 30, 2020			2

Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended December 31, 2020 and 2019 (Unaudited)			3

Consolidated Statements of Stockholders’ Equity for each of the Three and Six Months in the Period Ended December 31, 2020 and 2019 (Unaudited)			4

Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2020 and 2019 (Unaudited)			6

Notes to Consolidated Financial Statements (Unaudited)			7

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			22

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk			31

ITEM 4. Controls and Procedures			31

PART II-OTHER INFORMATION

ITEM 1. Legal Proceedings			32

ITEM 1A. Risk Factors			32

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds			32

ITEM 3. Defaults Upon Senior Securities			32

ITEM 4. Mine Safety Disclosures			32

ITEM 5. Other Information			32

ITEM 6. Exhibits			33

SIGNATURES			25

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Report contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact included in this Report, regarding our strategy, future operations, financial position, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this Report, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project,” or the negative of these terms, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and factors include:

•

the success of our plans to develop and potentially commercialize our product candidates;

•

the timing of the initiation and completion of preclinical studies and clinical trials;

•

the timing and sufficiency of patient enrollment and dosing in any future clinical trials;

•

the timing of the availability of data from clinical trials;

•

the timing and outcome of regulatory filings and approvals;

•

unanticipated delays;

•

sales, marketing, manufacturing and distribution requirements;

•

market competition and the acceptance of our products in the marketplace;

•

regulatory developments in the United States of America;

•

the development of novel AAV vectors;

•

the plans of licensees of our technology;

•

the clinical utility and potential attributes and benefits of ddRNAi and our product candidates,

•

including the potential duration of treatment effects and the potential for a “one shot” cure;

•

our dependence on our relationships with collaborators and other third parties;

•

expenses, ongoing losses, future revenue, capital needs and needs for additional financing;

•

the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan;

•

our intellectual property position and the duration of our patent portfolio;

•

the impact of local, regional, and national and international economic conditions and events; and

•

the impact of the current COVID-19 pandemic, the disease caused by the SARS-CoV-2 virus, which may adversely impact our business and preclinical and future clinical trials;

as well as other risks detailed under the caption “Risk Factors” in this Report and in other reports filed with the SEC. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Report, we caution you that these statements are based on a combination of facts and important factors currently known by us and our expectations of the future, about which we cannot be certain.

We have based the forward-looking statements included in this Report on information available to us on the date of this Report or on the date thereof. Except as required by law we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.

All forward-looking statements included herein or in documents incorporated herein by reference are expressly qualified in their entirety by the cautionary statements contained or referred to elsewhere in this Report.

PART I

FINANCIAL INFORMATION

BENITEC BIOPHARMA INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS


	Page
Consolidated Balance Sheets as of December 31, 2020 (Unaudited) and June 30, 2020		2
Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended December 31, 2020 and 2019 (Unaudited)		3
Consolidated Statements of Stockholders’ Equity for each of the Three and Six Months in the Period Ended December 31, 2020 and 2019 (Unaudited)		4
Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2020 and 2019 (Unaudited)		6
Notes to Consolidated Financial Statements (Unaudited)		7

BENITEC BIOPHARMA INC.

Consolidated Balance Sheets

(in thousands, except par value and share amounts)


	December 31,			June 30,
	2020			2020
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	14,010		$	9,801
Trade and other receivables		21			59
Other current assets		352			949

Total current assets		14,383			10,809
Property and equipment, net		610			374
Deposits		9			9
Other assets		210			—
Right-of-use assets		300			395

Total assets	$	15,512		$	11,587

Liabilities and Stockholders’ Equity
Current liabilities:
Trade and other payables	$	355		$	741
Accrued employee benefits		221			203
Lease liabilities, current portion		203			192

Total current liabilities		779			1,136
Lease liabilities, less current portion		108			213

Total liabilities		887			1,349
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.0001 par value—10,000,000 shares authorized; 4,540,469 and 1,108,374 shares issued and outstanding at December 31, 2020 and June 30, 2020, respectively		4			1
Additional paid-in capital		138,395			128,826
Accumulated deficit		(122,207	)		(116,636	)
Accumulated other comprehensive loss		(1,567	)		(1,953	)

Total stockholders’ equity		14,625			10,238

Total liabilities and stockholders’ equity	$	15,512		$	11,587

The accompanying notes are an integral part of these consolidated financial statements.

BENITEC BIOPHARMA INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2020			2019			2020			2019
Revenue:
Revenues from customers	$	1		$	77		$	56		$	110

Total revenues		1			77			56			110
Operating expenses
Royalties and license fees		(19	)		(306	)		114			(280	)
Research and development		1,168			599			1,942			1,022
General and administrative		2,111			1,895			3,948			2,645

Total operating expenses		3,260			2,188			6,004			3,387

Loss from operations		(3,259	)		(2,111	)		(5,948	)		(3,277	)
Other income (loss):
Foreign currency transaction gain (loss)		—			5			(54	)		5
Interest income (expense), net		(2	)		17			(3	)		35
Other income, net		10			—			36			—
Unrealized loss on investment		(1	)		(1	)		(1	)		—

Total other income (loss), net		7			21			(22	)		40

Net loss	$	(3,252	)	$	(2,090	)	$	(5,970	)	$	(3,237	)

Other comprehensive income:
Unrealized foreign currency translation gain		208			336			386			32

Total other comprehensive income		208			336			386			32

Total comprehensive loss	$	(3,044	)	$	(1,754	)	$	(5,584	)	$	(3,205	)

Net loss	$	(3,252	)	$	(2,090	)	$	(5,970	)	$	(3,237	)

Net loss per share:
Basic and diluted	$	(0.76	)	$	(2.00	)	$	(2.21	)	$	(3.40	)

Weighted average number of shares outstanding: basic and diluted		4,300,073			1,043,431			2,704,223			951,112

The accompanying notes are an integral part of these consolidated financial statements.

BENITEC BIOPHARMA INC.

Consolidated Statements of Stockholders’ Equity

(Unaudited)

(in thousands, except share amounts)


	Common Stock				Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
	Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
Balance at June 30, 2019		856,765	$	1	$	127,327		$	(108,870	)	$	(1,864	)	$	16,594
Common stock sold for cash, net of issuance costs of $240		186,666		—		1,720			—			—			1,720
Issuance of pre-purchased warrants, net of issuance costs of $240		—		—		50			—			—			50
Share-based compensation		—		—		55			—			—			55
Forfeiture of share-based payments		—		—		(61	)		61			—			—
Foreign currency translation loss		—		—		—			—			(304	)		(304	)
Net loss		—		—		—			(1,147	)					(1,147	)

Balance at September 30, 2019		1,043,431	$	1	$	129,091		$	(109,956	)	$	(2,168	)	$	16,968

Share-based compensation		—		—		37									37

Forfeiture of share-based payments		—		—		(319	)		319			—			—

Foreign currency translation gain		—		—		—			—			336			336

Net loss		—		—		—			(2,090	)		—			(2,090	)

Balance at December 31, 2019		1,043,431	$	1	$	128,809		$	(111,727	)	$	(1,832	)	$	15,251

The accompanying notes are an integral part of these consolidated financial statements.

BENITEC BIOPHARMA INC.

Consolidated Statements of Stockholders’ Equity

(Unaudited)

(in thousands, except share amounts)


	Common Stock				Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
	Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
Balance at June 30, 2020		1,108,374	$	1	$	128,826		$	(116,636	)	$	(1,953	)	$	10,238
Share-based compensation		—		—		38			—			—			38
Forfeiture of share-based payments		—		—		(14	)		14			—			—
Foreign currency translation gain		—		—		—			—			178			178
Net loss		—		—		—			(2,718	)					(2,718	)

Balance at September 30, 2020		1,108,374	$	1	$	128,850		$	(119,340	)	$	(1,775	)	$	7,736

Issuance of common stock and pre-funded warrants sold for cash, net of issuance costs of $1,643		3,150,514		3		9,848			—			—			9,851

Exercise of pre-funded warrants		281,581		—		—			—			—			—

Share-based compensation		—		—		82			—			—			82

Forfeiture of share-based payments		—		—		(385	)		385			—			—

Foreign currency translation gain		—		—		—			—			208			208

Net loss		—		—		—			(3,252	)		—			(3,252	)

Balance at December 31, 2020		4,540,469	$	4	$	138,395		$	(122,207	)	$	(1,567	)	$	14,625

The accompanying notes are an integral part of these consolidated financial statements.

BENITEC BIOPHARMA INC.

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)


	Six Months Ended
	December 31,
	2020			2019
Cash flows from operating activities:
Net loss	$	(5,970	)	$	(3,237	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		112			102
Amortization of right-of-use assets		95			91
Loss on disposal of fixed assets		—			1
Unrealized (gain) loss on investment		(1	)		1
Share-based compensation expense		120			92
Changes in operating assets and liabilities:
Trade and other receivables		28			1,566
Other assets		424			(150	)
Trade and other payables		(425	)		(2,028	)
Accrued employee benefits		25			11
Lease liabilities		(94	)		(70	)

Net cash used in operating activities		(5,686	)		(3,621	)

Cash flows from investing activities:
Purchases of property and equipment		(347	)		(82	)
Proceeds from disposal of property and equipment		—			1

Net cash used in investing activities		(347	)		(81	)

Cash flows from financing activities:
Proceeds from issues of shares and pre-funded warrants		11,494			2,250
Shares and pre-funded warrant issuance costs		(1,643	)		(480	)

Net cash provided by financing activities		9,851			1,770

Effects of exchange rate changes on cash and cash equivalents		391			—

Net increase (decrease) in cash and cash equivalents		4,209			(1,932	)
Cash and cash equivalents, beginning of period		9,801			15,718

Cash and cash equivalents, end of period	$	14,010		$	13,786

Supplemental disclosure of cash flow information:
Initial measurement of operating lease right-of-use assets and liabilities	$	—		$	(579	)

The accompanying notes are an integral part of these consolidated financial statements.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

1. Business

Benitec Biopharma Inc. (the “Company”) is a corporation formed under the laws of Delaware, United States of America, on November 22, 2019 and listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BNTC”. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (“BBL”). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April 15, 2020. On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company’s business focuses on the development of novel genetic medicines. Our proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes.

On November 27, 2019, BBL announced its intention to re-domicile from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the re-domiciliation, acquired all BBL shares and BBL became a wholly-owned subsidiary of Benitec Biopharma Inc.. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL’s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company’s common stock for every three ADSs held. The re-domiciliation was completed on April 15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March 26, 2020 and by the Supreme Court of Queensland on March 30, 2020.

In accordance with the U.S. Securities and Exchange Commission’s (“SEC”) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company’s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 ratio and share consolidation as if it occurred on July 1, 2019.

The terms the “Company,” “we,” “us,” “our” and similar terms used herein refer (i), prior to the re-domiciliation to BBL, an Australian corporation, and its subsidiaries, and (ii), following the re-domiciliation, to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).

The Company’s fiscal year end is June 30. References to a particular “fiscal year” are to our fiscal year end June 30 of that calendar year.

The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:


	Principal place of business/country of incorporation	Ownership Fiscal Year 2020			Ownership Fiscal Year 2019
Benitec Biopharma Proprietary Limited (“BBL”)	Australia		100	%		—
Benitec Australia Proprietary Limited	Australia		100	%		100	%
Benitec Limited	United Kingdom		100	%		100	%
Benitec, Inc.	USA		100	%		100	%
Benitec LLC	USA		100	%		100	%
RNAi Therapeutics, Inc.	USA		100	%		100	%
Tacere Therapeutics, Inc.	USA		100	%		100	%

The Company is continuing to monitor the impact of the pandemic of the novel strain of coronavirus COVID-19 (“COVID-19”) on all aspects of its business, including how it will impact our employees, suppliers, vendors and business partners. While the Company did experience some disruption from COVID-19 including disruption of the timing and completion of certain pre-clinical trials we are unable to predict the overall impact that COVID-19 will have on our financial position and operating results due to numerous uncertainties.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The Company’s consolidated financial statements contained in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020.

Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities.

Principles of Consolidation

The consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Foreign Currency Translation and Other Comprehensive Income (Loss)

The Company’s functional currency and reporting currency is the United States dollar. BBL’s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translation are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss).

Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).

Fair Value Measurements

The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities.

The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:


		Level 1:		Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

		Level 2:		Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

		Level 3:		Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

The carrying amounts of the Company’s cash and cash equivalents, accounts receivables, and accounts payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of December 31, 2020, and June 30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets.

Concentrations of Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

Trade and Other Receivables

As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical write-off experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives:


		Software		3-4 years
		Lab equipment		3-7 years
		Furniture and fixtures		3-7 years
		Computer hardware		3-5 years
		Leasehold improvements		shorter of the lease term or estimated useful lives

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Impairment of Long-Lived Assets

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

Trade and other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Leases

At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.

After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.

Basic and Diluted Net Income (Loss) Per Share

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of December 31, 2020, and 2019, there were 384,676 and 252,516 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Revenue Recognition

The Company adopted ASC 606 – Revenue from Contracts with Customers (“ASC 606”) on July 1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements.

Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606.

Management has also made the judgement that the grant of the license and transfer of associated know-how and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and know-how and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of know-how has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.

Licensing revenues

Revenue from licensees of the Company’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied.

The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due.

Royalties

Revenue from licensees of the Company’s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer’s subsequent sales of product occurs.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Services revenue

Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed.

Government Research and Development Grants

Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating.

Grant income is generated through the Australian federal government’s Research and Development Tax Incentive program, under which the government provides a cash refund for 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made.

The Company will not be claiming the Australian Government research and development grants going forward.

Research and Development Expense

Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and pre-clinical trials. Pre-clinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.

Equity-based Compensation Expense

The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and non-employee share-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company adopted FASB Accounting Standard Update (“ASU”) 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Income Taxes

The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 Accounting for Income Taxes, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized.

For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13: Financial Instruments – Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management’s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (“SRC”) as of November 15, 2019. As such, ASU 2019-10: Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023.

3. Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended December 31, 2020, and 2019, the Company incurred a net loss of $6.0 million and $3.2 million and used net cash of $5.7 million and $3.6 million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future.

As of December 31, 2020, the Company had $14 million in cash and cash equivalents. The Company has performed a review of the cash flow forecasts and believes that the current funding will be sufficient for a period of at least twelve months from the date of this report.

The Company’s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

4. Revenue (US$’000)


	Three Months Ended				Six Months Ended
Revenues from customers	December 31, 2020		December 31, 2019		December 31, 2020		December 31, 2019
Licensing revenue	$	1	$	61	$	56	$	61
Royalty revenue		—		16		—		45
Service revenue*		—		—		—		4

Total	$	1	$	77	$	56	$	110

On July 9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company’s product BB-301, which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company’s intellectual property related to BB-301 and the transfer of the right to use the intellectual property of the Company’s BB-301 license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June 6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September 3, 2019. The termination discharges all future performance obligations at termination date under the contract.


	Three Months Ended December 31, 2020
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		1		—		—		1

Total	$	1	$	—	$	—	$	1


	Six Months Ended December 31, 2020
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		56		—		—		56

Total	$	56	$	—	$	—	$	56

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)


	Three Months Ended December 31, 2019
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		61		16		—		77

Total	$	61	$	16	$	—	$	77


	Six Months Ended December 31, 2019
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	4	$	4
Services transferred over time		61		45		—		106

Total	$	61	$	45	$	4	$	110

5. Cash and Cash equivalents


(US$’000)	December 31, 2020		June 30, 2020
Cash at Bank	$	14,010	$	5,231
Term Deposit		—		4,570

Total	$	14,010	$	9,801

6. Trade and other receivables


(US$’000)	December 31, 2020		June 30, 2020
Other receivables	$	21	$	59

Total	$	21	$	59

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

7. Other assets


(US$’000)	December 31, 2020			June 30, 2020
Prepaid expenses	$	538		$	861
Security deposit		16			69
Other deposit		7			18
Market value of listed shares		1			1

Total other assets		562			949
Less: non-current portion		(210	)		—

Current portion	$	352		$	949

8. Property and equipment, net


(US$’000)	December 31, 2020			June 30, 2020
Software	$	11		$	11
Lab equipment		1,457			1,109
Computer hardware		26			26
Leasehold improvements		24			24

Total property and equipment, gross		1,518			1,170
Accumulated depreciation and amortization		(908	)		(796	)

Total property and equipment, net	$	610		$	374

Depreciation expense was $67,000 and $112,000 for the three months and six months ended December 31, 2020, respectively, and $51,000 and $102,000, respectively, for the same periods in 2019.

9. Trade and other payables


(US$’000)	December 31, 2020		June 30, 2020
Trade payable	$	87	$	282
Accrued license fees		142		54
Accrued professional fees		35		155
Other payables		91		250

Total	$	355	$	741

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

10. Leases

The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company’s lease does not contain any residual value guarantees or material restrictive covenants.

As of December 31, 2020, the Company’s operating lease has a remaining lease term of 1.45 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows:


(US$’000)	December 31, 2020
2021	$	105
2022		218

Total operating lease payments		323
Less imputed interest		(12	)

Present value of operating lease liabilities	$	311

The Company recorded lease liabilities and right-of-use lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company’s incremental borrowing rate. Rent expense was $52,000 and $104,000 for the three months and six months ended December 31, 2020, respectively, and $52,000 and $104,000, respectively, for the same periods in 2019.

11. Stockholders’ equity

Common Stock

On October 6, 2020, the Company announced the closing of an underwritten public offering of 2,666,644 shares of its common stock at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the offering price of $3.10 per share.

Warrants

On October 6, 2020, the Company announced the closing of an underwritten public offering of 559,162 shares of common stock underlying pre-funded warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share (“Pre-Funded Warrants”). Of the 559,162 Pre-Funded Warrants issued, 281,581 Pre-Funded Warrants had been exercised as of December 31, 2020. The remaining Pre-Funded Warrants may be exercised at any time from issuance.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

The activity related to warrants during for the three and six months ended December 31, 2020, is summarized as follows:


	Common Stock from Warrants			Weighted- average Exercise Price (per share)
Outstanding at July 1, 2020		145,421		$	29.48
Granted		—			—
Exercised		—			—
Forfeited		(38,326	)		82.50
Outstanding and exercisable at September 30, 2020		107,095		$	10.50
Granted		559,162			3.09
Exercised		(281,581	)		3.10
Forfeited		—			—
Outstanding and exercisable at December 31, 2020		384,676		$	5.15

Equity Incentive Plan

Employee Share Option Plan

Upon the re-domiciliation, the Company assumed BBL’s obligations with respect to the settlement of options that were issued by BBL prior to the re-domiciliation pursuant to the Benitec Officers’ and Employees’ Share Option Plan (the “Share Option Plan”). This includes the Company’s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. After the re-domiciliation, no new options have been or will be issued under the Share Option Plan.

Equity and Incentive Compensation Plan

On December 9, 2020, the Company’s stockholders approved the Company’s 2020 Equity and Incentive Compensation Plan (the “2020 Plan”). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company’s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of one-third on each anniversary of the applicable grant date for three years. Non-employee director options vest in increments of one-third on the day prior to each of the Company’s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Any future equity grants will be made under the 2020 Plan.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

Equity Awards

The activity related to equity awards, which comprised of stock options during the three and six months ended December 31, 2020, is summarized as follows:


	Stock Options			Weighted- average Exercise Price		Weighted-average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at June 30, 2020		70,161		$	60.42		2.89 years	$	—
Granted		—			—
Exercised		—			—
Forfeited		(444	)		69.32

Outstanding at September 30, 2020		69,717		$	60.00		2.65 years		—
Exercisable at September 30, 2020		43,273		$	68.53		2.26 years	$	—

Granted		525,546			2.98		9.95 years
Exercised		—			—
Forfeited		(7,967	)		153.78

Outstanding at December 31, 2020		587,296			7.64		9.2 years		—
Exercisable at December 31, 2020		35,473		$	48.18		2.4 years	$	—

Share-Based Compensation Expense

The classification of share-based compensation expense is summarized as follows:


	Three Months Ended December 31,				Six Months Ended December 31,
(US$’000)	2020		2019		2020		2019
Research and development	$	6	$	17	$	15	$	—
General and administrative		76		20		105		92

Total share-based compensation expense	$	82	$	37	$	120	$	92

As of December 31, 2020, there was $1,393,000 of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan.

BENITEC BIOPHARMA INC.

Notes to Consolidated Financial Statements

(Unaudited)

12. Income taxes

For the three and six months ended December 31, 2020, and 2019, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is more likely than not that the benefit will not be realized.

13. Commitments and contingencies

Contract commitments

The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments.

Contingencies

From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of financial condition and operating results together with our consolidated financial statements and the related notes and other financial information included elsewhere in this document.

Overview

We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical needs via the application of the silence and replace approach to the treatment of genetic disorders.

Benitec Biopharma Inc. (“Benitec” or the “Company” or in the third person, “we” or “our”) is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.

BB-301 is the most advanced ddRNAi-based genetic medicine currently under development by Benitec. BB-301 is an internally optimized, AAV-based gene therapy agent that is designed to both silence the expression of mutated, disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and replace the mutant genes with normal, “wild type” genes (to drive restoration of function in diseased cells). This fundamental approach to disease management is called “silence and replace” and this biological mechanism offers the potential to restore the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has been granted Orphan Drug Designation in the United States and the European Union.

Through the combination of the targeted gene silencing effects of RNAi and the durable transgene expression achievable via the use of modified viral vectors, the silence and replace approach has the potential to produce long-term silencing of disease-causing genes along with simultaneous replacement of wild type gene function following a single administration of the proprietary genetic medicine. We believe this novel attribute of the investigational agents under development by Benitec may facilitate the achievement of robust clinical activity while greatly reducing the dosing frequencies traditionally expected for medicines employed for the management of chronic diseases. Additionally, the establishment of chronic gene silencing and gene replacement may significantly reduce the risk of patient non-compliance during the course of medical management of potentially fatal clinical disorders.

Unless otherwise indicated, all dollar amounts in this section are provided in thousands.

Re-domiciliation

On April 15, 2020, (the “Implementation Date”), the re-domiciliation of Benitec Limited (the “Re-domiciliation”), a public company incorporated under the laws of the State of Western Australia, or Benitec Limited, was completed in accordance with the Scheme Implementation Agreement, as amended and restated as of January 30, 2020, between Benitec Limited and us. As a result of the Re-domiciliation, the jurisdiction of incorporation was changed from Australia to Delaware, and Benitec Limited became our wholly owned subsidiary.

The Re-domiciliation was effected pursuant to a statutory scheme of arrangement under Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of our common stock, on the basis of one share of our common stock, par value $0.0001 per share, for every 300 ordinary shares of Benitec Limited issued and outstanding. Holders of Benitec Limited’s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of our common stock for every three ADSs held.

COVID-19

In December 2019, an outbreak of a novel strain of coronavirus was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to nearly every country, including Australia and the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.

Certain of our research and development efforts are conducted globally, including the ongoing development of our silence and replace therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to initiate preclinical and clinical studies despite the ongoing COVID-19 pandemic. As we continue to actively advance our preclinical programs, including our ongoing tissue transduction studies for BB-301, we are in close contact with our principal investigators and preclinical trial sites, which are primarily located in the France, and are assessing the impact of COVID-19 on our studies and the expected development timelines and costs of all of our product candidates, on an ongoing basis. In light of recent developments relating to the COVID-19 global pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA’s updated industry guidance for conducting clinical trials issued on March 18, 2020, we have experienced delays to the original timeline regarding the initiation and anticipated completion of the ongoing BB-301 IND-enabling development work. The initiation of the BB-301 tissue transduction study, which represents a key component of the IND-enabling work, was delayed by several months, however, the study has been recently initiated and the dosing of the initial preclinical cohorts has proceeded without incident. We will continue to evaluate the impact of the COVID-19 pandemic on our business and expect to reevaluate the timing of our anticipated preclinical and clinical milestones as we learn more and the impact of COVID-19 on our industry becomes more clear.

We had also implemented work-from-home measures for some of our employees between March 2020 and December 2020, resulting in a reduction of laboratory work and a halt of non-essential business travel. As we transition our employees back to our premises, there is a risk that COVID-19 infections occur at our offices or laboratory facilities and significantly affect our operations. Additionally, if any of our critical vendors are impacted, our business could be affected if we become unable to timely procure essential equipment, supplies or services in adequate quantities and at acceptable prices.

Axovant Termination

Benitec’s License and Collaboration Agreement, dated July 9, 2018, with Axovant Sciences GmbH, or Axovant, was terminated as of September 3, 2019. As a result, all rights and licenses which Benitec had granted to Axovant to develop and commercialize BB-301 and related gene therapy product candidates terminated.

Prior to such termination, the Benitec team endeavored to conduct several additional exploratory nonclinical analyses in order to potentially improve the biological efficacy of BB-301 via further optimization of the route of administration employed to dose the target muscle tissues.

Nonclinical data derived from in vivo evaluations of BB-301 in two distinct large animal species suggested the existence of an opportunity to further improve the biological efficacy of the compound via additional optimization of the proprietary delivery method employed to dose key target tissues that underlie the morbidity and mortality associated with the natural history of OPMD. The initial biological efficacy profile observed for BB-301 following in vivo testing in the A17 mouse model of OPMD, including full correction of the disease phenotype, remained unchanged. However, the Benitec management team desired to complete a series of exploratory analyses prior to the formal IND filing and the subsequent initiation of clinical testing.

Completion of the experimental work noted above would have delayed the initiation of the BB-301 clinical study beyond the timelines that were initially outlined by Axovant following the execution of the License and Collaboration Agreement between Benitec and Axovant. As such, Axovant elected to terminate the License and Collaboration Agreement between Benitec and Axovant, and all rights and licenses granted to Axovant terminated, including the rights to BB-301, which was in preclinical development for the treatment of OPMD, and all other early stage research collaboration programs that were governed by the agreement.

Nonclinical Programs

Nonclinical research efforts supporting the development of ddRNAi-based therapeutic agents and silence and replace-based therapeutic agents targeting the treatment of Chronic Hepatitis B Virus Infection (“HBV”) and Age-Related Macular Degeneration (“AMD”) have concluded and are no longer being continued by the Company.

Workforce Reduction

On July 31, 2019, Benitec announced the completion of a workforce reduction of approximately 50%. Through this streamlining of operations, the Company retained staff members who are key to the achievement of the core research and development goals. The rationalization of resources was deemed to be supportive of an extended financial runway for the Company while allowing Benitec to continue to advance the BB-301 program.

Royalties, milestone payments and other license fees

We are required to pay royalties, milestone payments and other license fees in connection with our licensing of intellectual property from third parties, including as discussed below.

In December 2016, we entered into an exclusive sublicense agreement with NantWorks, LLC, pursuant to which we agreed to make certain milestone and royalty payments, as well as periodic payments for so long as the agreement remained in effect. In December of 2018, the Company accrued a milestone payment of USD 300k (AUD 425,411), which was anticipated to be paid to NantWorks, LLC under the sublicense agreement. It was later determined that the milestone was not required to be paid and, therefore, the accrual was reversed in December of 2019. We terminated the exclusive sublicense agreement for convenience, with the termination effective as of June 2020.

We have collaborated with Biomics Biotechnologies Co., Ltd., or Biomics, pursuant to several collaboration agreements in relation to single-stranded RNA and shRNA sequences for treatment of hepatitis B. In July 2015, we entered into an earn-out agreement with Biomics which confirmed Benitec’s ownership of certain patents resulting from the collaboration in exchange for an upfront payment and equity issuance to Biomics and a share of certain future licensing revenue received by Benitec.

Foreign Currency Translation and Other Comprehensive Income (Loss)

Other comprehensive income (loss) for all periods presented includes only foreign currency translation gains (losses).

October 2020 Capital Raise

On October 6, 2020, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents (the “October 2020 Capital Raise”). The Company received gross proceeds of approximately $11.5 million and net proceeds of approximately $9.9 million from the offering.

Results of Operations

Revenues

In the past Benitec Limited has generated revenue from its operations through two activities: revenue from customers and revenue from government research and development grants. In the fiscal year ended June 30, 2020 and the six months ended December 31, 2020, the Company generated funds primarily from capital raising activities. For the three-month period ended December 31, 2020, the Company received $1 in revenue relating to licensing fees. The Company has not generated any revenues from the sales of products. Revenues from licensing fees are included in the revenue from customers line item on our statements of operations and comprehensive income (loss). There were no Research and Development Tax Incentive payments received during this period.

Our licensing fees have been generated through the licensing of our ddRNAi technology to biopharmaceutical companies, and in the fiscal year-ended June 30, 2019, revenue was generated through a License and Collaboration Agreement with Axovant Sciences (the “Axovant Agreement”).

The following table sets forth a summary of our revenues for each of the periods set forth below:


	Three Months Ended December 31,				Six Months Ended December 31,
	2020		2019		2020		2019
	(US$’000)
Revenues:
Revenues from customers	$	1	$	77	$	56	$	110

Total revenues	$	1	$	77	$	56	$	110

Revenues from customers

On July 9, 2018, the Company entered into the Axovant Agreement. The Axovant Agreement granted Axovant Sciences an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company’s product known as BB-301, which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Service revenue consists of payments for services provided to Axovant Sciences pursuant to the Axovant Agreement. On June 6, 2019, the termination of the Axovant Agreement was announced. The termination of the Axovant Agreement was effective as of September 3, 2019. The termination discharges all future performance obligations under the contract at the termination date.

During the three and six months ended December 31, 2020, respectively, the Company recognized $1 and $56 in customer revenues, as compared to $77 and $110 for the comparable periods ended December 31, 2019. The decrease in revenues from customers is due to the decrease in licensing and royalty revenues in the current period.

Research and Development Expenses

Research and development expenses relate primarily to the cost of conducting clinical and pre-clinical trials. Pre-clinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, related benefits, travel, and equity-based compensation expense. General and administrative expenses also include facility expenses, professional fees for legal, consulting, accounting and audit services and other related costs.

We anticipate that our general and administrative expenses may increase as the Company focuses on the continued development of the pre-clinical OPMD program. The Company also anticipates an increase in expenses relating to accounting, legal and regulatory-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and other costs associated with being a domestic public company after the Re-domiciliation and no longer a “foreign private issuer” under SEC rules.

Operating Expenses

The following tables set forth a summary of our expenses for each of the periods set forth below:


	Three Months Ended December 31,						Six Months Ended December 31,
	2020			2019			2020		2019
	(US$’000)
Operating Expenses:
Royalties and license fees	$	(19	)	$	(306	)	$	114	$	(280	)
Research and development		1,168			599			1,942		1,022
General and administrative		2,111			1,895			3,948		2,645

Total operating expenses	$	3,260		$	2,188		$	6,004	$	3,387

During the three and six months ended December 31, 2020, respectively, we incurred ($19) and $114 in royalties and license fees, as compared to ($306) and ($280) for the comparable periods ended December 31, 2019. The change is due to a reversal of an accrual which created the negative balance in the three and six months ended 2019. In the three months ended December 2020 we also reversed an accrual, resulting in the balance of ($19) as opposed to the six month balance which included a payable license fee.

During the three and six months ended December 31, 2020, we incurred $1,168 and $1,942 in research and development expenses, as compared to $599 and $1,022 for the comparable periods ended December 31, 2019. The increase in research and development expenses are related to the pre-clinical trials associated with BB-301.

General and administrative expense was $2,111 and $3,948 for the three and six months ended December 31, 2020 and 2019, respectively, as compared to $1,895 and $2,645 for the comparable periods ended December 31, 2019. This increase was due to the increase in insurance, consultants, legal and accounting fees.

Other Income (Expense)

The following tables set forth a summary of our other income (loss) for each of the periods set forth below:


	Three Months Ended December 31,						Six Months Ended December 31,
	2020			2019			2020			2019
	(US$’000)
Other Income (Loss):
Foreign currency transaction gain (loss)	$	—		$	5		$	(54	)	$	5
Interest income (expense), net		(2	)		17			(3	)		35
Other income, net		10			—			36			—
Unrealized loss on investment		(1	)		(1	)		(1	)		—

Total other income (loss), net	$	7		$	21		$	(22	)	$	40

The other income (loss), net during the three and six months ended December 31, 2020, respectively, totaled $7 and ($22), which consists of foreign currency transaction loss, interest expense, other income, and unrealized loss on investment. During the three and six months ended December 31, 2019, respectively, other income, net totaled $21 and $40. Foreign currency transaction gain has decreased due to a change in foreign exchange rates. Interest income (expense), net has decreased due to fewer transactions with interest. Other income, net increased due to COVID-19 stimulus incentives from the Australian government. Unrealized loss on investment remained unchanged for the three months ended December 31, 2020, compared to the three months ended December 31, 2019.

Net Loss

The following tables set forth a summary of our loss for each of the periods set forth below:


	Three Months Ended December 31,						Six Months Ended December 31,
	2020			2019			2020			2019
	(US$’000)
Net Loss	$	(3,252	)	$	(2,090	)	$	(5,970	)	$	(3,237	)

As a result of the changes in revenues and expenses noted above, our net loss increased from approximately $2,090 and $3,237 in the three and six months ended December 31, 2019, respectively, to $3,252 and $5,970 in the three and six months ended December 31, 2020.

Liquidity and Capital Resources

The Company has incurred cumulative losses and negative cash flows from operations since our predecessor’s inception in 1995. The Company had accumulated losses of $122.2 million as of December 31, 2020. We expect that our research and development expenses may increase due to the continued development of the OPMD program. It is also likely that there will be an increase in the general and administrative expenses due to the obligations of being a domestic public company in the United States as a result of the Re-domiciliation and no longer a “foreign private issuer” under SEC Rules.

We had no borrowings for the three months ended December 31, 2020 and 2019 and do not currently have a credit facility.

As of December 31, 2020, we had cash and cash equivalents of approximately $14 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts.

The following table sets forth a summary of the net cash flow activity for each of the periods set forth below:


	Six Months Ended December 31,
	2020			2019
	(US$’000)
Net cash provided by (used in):
Operating activities	$	(5,686	)	$	(3,621	)
Investing activities		(347	)		(81	)
Financing activities		9,851			1,770
Effects of exchange rate changes on cash and cash equivalents		391			—

Net increase (decrease) in cash	$	4,209		$	(1,932	)

Operating activities

Net cash used in operating activities for the six months ended December 31, 2020 and 2019 was $5,686 and $3,621, respectively. Net cash used in operating activities was primarily the result of our net loss and change in working capital and a decrease in payables.

Investing activities

Net cash used in investing activities for the six months ended December 31, 2020 was $347. Net cash used in investing activities for the six months ended December 31, 2019 was $81. The change was primarily related to an increase in purchases of equipment in 2020 compared to the same period in 2019.

Financing activities

Net cash provided by financing activities was $9,851 and $1,770 for the six months ended December 31, 2020 and 2019, respectively. Cash from financing activities related to the issuance of common stock, including $11,494 in gross proceeds from the October 2020 Capital Raise, partially offset by $1,643 in share issuance costs for the period ended December 31, 2020. For the same period in 2019, cash from financing activities related to the issuance of common stock of BBL, including gross proceeds of $2,250 from a public offering, partially offset by $480 in share issuance costs.

The future of the Company as an operating business will depend on its ability to generate revenues mostly from licensing, strategic alliances and collaboration arrangements with pharmaceutical companies. While we continue to progress discussions and advance opportunities to engage with pharmaceutical companies and continue to seek licensing partners for ddRNAi in disease areas that are not our focus, there can be no assurance as to whether we will enter into such arrangements or what the terms of any such arrangement could be.

While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates.

Unless and until we establish significant revenues from licensing programs, strategic alliances or collaboration arrangements with pharmaceutical companies, or from product sales, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of product candidates and begin to prepare to commercialize any product that receives regulatory approval. We are subject to the risks inherent in the development of new gene therapy products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We estimate that our cash and cash equivalents will be sufficient to fund the Company’s operations at least for the next twelve months.

We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

•

the timing and costs of our planned clinical trials for our ddRNAi and silence and replace product candidates;

•

the timing and costs of our planned preclinical studies for our ddRNAi and silence and replace product candidates;

•

the number and characteristics of product candidates that we pursue;

•

the outcome, timing and costs of seeking regulatory approvals;

•

revenue received from commercial sales of any of our product candidates that may receive regulatory approval;

•

the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;

•

the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

•

the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and

•

the extent to which we need to in-license or acquire other products and technologies.

Contractual Obligations and Commercial Commitments

On July 9, 2018, the Company entered into an Agreement with Axovant Sciences. The Agreement granted Axovant Sciences an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company’s product known as BB-301, which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. On June 6, 2019, the termination of the Agreement with Axovant Sciences was announced. The termination of the Agreement was effective as of September 3, 2019. The termination discharges all future performance obligations at termination date under the contract.

On October 1, 2016, the Company entered into an operating lease for office space in Hayward , California that originally expired in April 2018. The Company has entered into lease amendments that extend the lease commitment through June 2022.

Off-Balance Sheet Arrangements

The Company had no material off-balance sheet arrangements as of December 31, 2020.

Critical Accounting Policies and Significant Accounting Estimates

The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of the Notes to Consolidated Financial Statements included in this Quarterly Report on Form 10-Q describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies.

A critical accounting policy is defined as one that is both material to the presentation of the Company’s consolidated financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on the Company’s financial condition or results of operations. Specifically, these policies have the following attributes: (1) the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2) different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on the Company’s financial condition or results of operations.

Estimates and assumptions about future events and their effects cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as the Company’s operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled “Risk Factors.” Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company’s consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States of America,and provide a meaningful presentation of the Company’s financial condition and results of operations.

Management believes that the following are critical accounting policies:

Revenue Recognition

The Company adopted and implemented on July 1, 2018, ASC 606—“Revenue from Contracts with Customers” (“ASC 606”). ASC 606 did not have a material impact on the consolidated financial statements.

Upon implementation of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Licensing revenues

Royalties

Services revenue

Share-Based Compensation

The Company records share-based compensation in accordance with ASC 718, “Stock Compensation”. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and non-employee share-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.

Recent Accounting Pronouncements

Accounting Standards recently adopted

None.

New Accounting Standards and Interpretations not yet mandatory or early adopted

ASU 2016-13—In June 2016, the FASB issued ASU No. 2016-13: “Financial Instruments—Credit Losses (Topic 326)”. This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management’s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (“SRC”) as of November 15, 2019. As such, ASU 2019-10: “Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates” amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information pursuant to this Item.

Item 4. Controls and Procedures

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). As of the end of the period covered by this report we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 of the Securities and Exchange Act of 1934, as amended. Based upon that evaluation, our principal executive officer and principal financial and accounting officer concluded that our disclosure controls and procedures are effective.

There were no changes in our internal controls over financial reporting during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We do not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not a party to any legal proceedings.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits.


Number		Description of Document

4.1		Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Company’s amended Form S-1 filed on October 1, 2020 (File No. 333-246314))

10.1		Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on December 14, 2020)

10.2		Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan (Executives) (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on December 15, 2020)

10.3		Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan (Non-Employee Directors) (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed on December 15, 2020)

31.1		Statement of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Statement of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Statement of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

32.2		Statement of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema Document*

101.CAL		XBRL Calculation Linkbase Document*

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB		XBRL Label Linkbase Document*

101.PRE		XBRL Taxonomy Presentation Linkbase Document*

*	Filed herewith.

**	Furnished, not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.


						Benitec Biopharma Inc.

Dated: February 9, 2021						/s/ Megan Boston
						Megan Boston
						Executive Director (principal financial and accounting officer)

						/s/ Jerel Banks
						Jerel Banks
						President and Chief Executive Officer (principal executive officer)

EX-31.1 2 d125513dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

Statement Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by

Principal Executive Officer

Regarding Facts and Circumstances Relating to Exchange Act Filings

I, Jerel Banks, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Benitec Biopharma Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 9, 2021

/s/ Jerel Banks

Jerel Banks

President and Chief Executive Officer

EX-31.2 3 d125513dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

Statement Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by

Principal Financial Officer

Regarding Facts and Circumstances Relating to Exchange Act Filings

I, Megan Boston, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Benitec Biopharma Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 9, 2021

/s/ Megan Boston

Megan Boston

Executive Director (principal financial and accounting officer)

EX-32.1 4 d125513dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

Statement Pursuant to Section 906 the Sarbanes-Oxley Act of 2002

Principal Executive Officer

Regarding Facts and Circumstances Relating to Exchange Act Filings

Dated: February 9, 2021

I, Jerel Banks, Chief Executive Officer of Benitec Biopharma Inc., hereby certify, to my knowledge, that:

1. the accompanying Quarterly Report on Form 10-Q of Benitec Biopharma Inc. for the three month period ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities and Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Benitec Biopharma Inc.

IN WITNESS WHEREOF, the undersigned has executed this Statement as of the date first written above.

/s/ Jerel Banks

Jerel Banks

President and Chief Executive Officer

EX-32.2 5 d125513dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

Statement Pursuant to Section 906 the Sarbanes-Oxley Act of 2002

Principal Financial Officer

Regarding Facts and Circumstances Relating to Exchange Act Filings

Dated: February 9, 2021

I, Megan Boston, Executive Director (principal accounting officer) of Benitec Biopharma Inc., hereby certify, to my knowledge, that:

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Benitec Biopharma Inc.

/s/ Megan Boston

Megan Boston

Executive Director (principal financial and accounting officer)

EX-101.INS 6 bntc-20201231.xml XBRL INSTANCE DOCUMENT 0001808898 2020-12-31 0001808898 2020-06-30 0001808898 2020-07-01 2020-12-31 0001808898 2019-07-01 2019-12-31 0001808898 2020-10-01 2020-12-31 0001808898 2019-10-01 2019-12-31 0001808898 2019-07-01 2019-09-30 0001808898 2019-11-27 2019-11-27 0001808898 2020-07-01 2020-09-30 0001808898 2021-02-04 0001808898 2019-06-30 0001808898 2019-12-31 0001808898 2020-09-30 0001808898 2019-09-30 0001808898 us-gaap:EquipmentMember 2020-12-31 0001808898 us-gaap:ComputerEquipmentMember 2020-12-31 0001808898 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001808898 us-gaap:SoftwareDevelopmentMember 2020-12-31 0001808898 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001808898 bntc:BenitecBiopharmaProprietaryLimitedBblMember 2020-12-31 0001808898 bntc:BenitecAustraliaProprietaryLimitedMember 2020-12-31 0001808898 bntc:BenitecLimitedMember 2020-12-31 0001808898 bntc:BenitecIncMember 2020-12-31 0001808898 bntc:BenitecLlcMember 2020-12-31 0001808898 bntc:RnaiTherapeuticsIncMember 2020-12-31 0001808898 bntc:TacereTherapeuticsIncMember 2020-12-31 0001808898 bntc:PreFundedWarrantsMember 2020-12-31 0001808898 us-gaap:EquipmentMember 2020-06-30 0001808898 us-gaap:ComputerEquipmentMember 2020-06-30 0001808898 us-gaap:LeaseholdImprovementsMember 2020-06-30 0001808898 us-gaap:SoftwareDevelopmentMember 2020-06-30 0001808898 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001808898 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001808898 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001808898 us-gaap:LicenseMember us-gaap:TransferredOverTimeMember 2020-10-01 2020-12-31 0001808898 us-gaap:TransferredOverTimeMember 2020-10-01 2020-12-31 0001808898 us-gaap:LicenseMember 2020-10-01 2020-12-31 0001808898 us-gaap:RoyaltyMember 2020-10-01 2020-12-31 0001808898 us-gaap:ServiceMember 2020-10-01 2020-12-31 0001808898 us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0001808898 us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2020-12-31 0001808898 us-gaap:EmployeeStockOptionMember 2020-10-01 2020-12-31 0001808898 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0001808898 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001808898 us-gaap:LicenseMember us-gaap:TransferredOverTimeMember 2019-10-01 2019-12-31 0001808898 us-gaap:RoyaltyMember us-gaap:TransferredOverTimeMember 2019-10-01 2019-12-31 0001808898 us-gaap:TransferredOverTimeMember 2019-10-01 2019-12-31 0001808898 us-gaap:LicenseMember 2019-10-01 2019-12-31 0001808898 us-gaap:RoyaltyMember 2019-10-01 2019-12-31 0001808898 us-gaap:ServiceMember 2019-10-01 2019-12-31 0001808898 us-gaap:ResearchAndDevelopmentExpenseMember 2019-10-01 2019-12-31 0001808898 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2019-12-31 0001808898 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2019-12-31 0001808898 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2019-07-01 2019-12-31 0001808898 us-gaap:TransferredAtPointInTimeMember 2019-07-01 2019-12-31 0001808898 us-gaap:LicenseMember us-gaap:TransferredOverTimeMember 2019-07-01 2019-12-31 0001808898 us-gaap:RoyaltyMember us-gaap:TransferredOverTimeMember 2019-07-01 2019-12-31 0001808898 us-gaap:TransferredOverTimeMember 2019-07-01 2019-12-31 0001808898 us-gaap:LicenseMember 2019-07-01 2019-12-31 0001808898 us-gaap:RoyaltyMember 2019-07-01 2019-12-31 0001808898 us-gaap:ServiceMember 2019-07-01 2019-12-31 0001808898 bntc:GrantReceivableOnResearchAndDevelopmentExpendituresMember 2019-07-01 2019-12-31 0001808898 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-12-31 0001808898 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-12-31 0001808898 bntc:BenitecBiopharmaProprietaryLimitedBblMember 2020-07-01 2020-12-31 0001808898 bntc:BenitecAustraliaProprietaryLimitedMember 2020-07-01 2020-12-31 0001808898 bntc:BenitecBiopharmaProprietaryLimitedMember 2020-07-01 2020-12-31 0001808898 bntc:BenitecLimitedMember 2020-07-01 2020-12-31 0001808898 bntc:BenitecIncMember 2020-07-01 2020-12-31 0001808898 bntc:BenitecLlcMember 2020-07-01 2020-12-31 0001808898 bntc:RnaiTherapeuticsIncMember 2020-07-01 2020-12-31 0001808898 bntc:TacereTherapeuticsIncMember 2020-07-01 2020-12-31 0001808898 us-gaap:LicenseMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-12-31 0001808898 us-gaap:TransferredOverTimeMember 2020-07-01 2020-12-31 0001808898 us-gaap:LicenseMember 2020-07-01 2020-12-31 0001808898 us-gaap:RoyaltyMember 2020-07-01 2020-12-31 0001808898 us-gaap:ServiceMember 2020-07-01 2020-12-31 0001808898 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-07-01 2020-12-31 0001808898 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-07-01 2020-12-31 0001808898 srt:MinimumMember bntc:LabEquipmentMember 2020-07-01 2020-12-31 0001808898 srt:MaximumMember bntc:LabEquipmentMember 2020-07-01 2020-12-31 0001808898 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-07-01 2020-12-31 0001808898 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-07-01 2020-12-31 0001808898 srt:MinimumMember us-gaap:ComputerEquipmentMember 2020-07-01 2020-12-31 0001808898 srt:MaximumMember us-gaap:ComputerEquipmentMember 2020-07-01 2020-12-31 0001808898 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-07-01 2020-12-31 0001808898 bntc:GrantReceivableOnResearchAndDevelopmentExpendituresMember 2020-07-01 2020-12-31 0001808898 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-12-31 0001808898 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0001808898 bntc:PreFundedWarrantsMember 2020-07-01 2020-12-31 0001808898 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001808898 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001808898 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001808898 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001808898 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001808898 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001808898 us-gaap:EmployeeStockOptionMember 2019-07-01 2020-06-30 0001808898 bntc:BenitecAustraliaProprietaryLimitedMember 2019-12-31 0001808898 bntc:BenitecLimitedMember 2019-12-31 0001808898 bntc:BenitecIncMember 2019-12-31 0001808898 bntc:BenitecLlcMember 2019-12-31 0001808898 bntc:RnaiTherapeuticsIncMember 2019-12-31 0001808898 bntc:TacereTherapeuticsIncMember 2019-12-31 0001808898 us-gaap:IPOMember 2020-10-06 0001808898 bntc:PreFundedWarrantsMember 2020-10-06 0001808898 us-gaap:OverAllotmentOptionMember 2020-10-06 0001808898 us-gaap:IPOMember 2020-10-06 2020-10-06 0001808898 bntc:PreFundedWarrantsMember 2020-10-06 2020-10-06 0001808898 us-gaap:OverAllotmentOptionMember 2020-10-06 2020-10-06 0001808898 us-gaap:EmployeeStockOptionMember 2020-12-31 0001808898 us-gaap:CommonStockMember 2020-12-31 0001808898 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001808898 us-gaap:RetainedEarningsMember 2020-12-31 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001808898 us-gaap:CommonStockMember 2019-12-31 0001808898 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001808898 us-gaap:RetainedEarningsMember 2019-12-31 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001808898 us-gaap:CommonStockMember 2019-06-30 0001808898 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001808898 us-gaap:RetainedEarningsMember 2019-06-30 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001808898 us-gaap:CommonStockMember 2019-09-30 0001808898 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001808898 us-gaap:RetainedEarningsMember 2019-09-30 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001808898 us-gaap:CommonStockMember 2020-06-30 0001808898 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001808898 us-gaap:RetainedEarningsMember 2020-06-30 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001808898 us-gaap:EmployeeStockOptionMember 2020-06-30 0001808898 us-gaap:EmployeeStockOptionMember 2020-09-30 0001808898 us-gaap:CommonStockMember 2020-09-30 0001808898 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001808898 us-gaap:RetainedEarningsMember 2020-09-30 0001808898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30

14010000

9801000

21000

59000

352000

949000

14383000

10809000

610000

374000

9000

300000

395000

15512000

11587000

355000

741000

221000

203000

192000

779000

1136000

108000

213000

887000

1349000

4000

1000

138395000

128826000

-122207000

-116636000

-1567000

-1953000

14625000

10238000

15512000

11587000

-5970000

-3237000

112000

102000

95000 91000

-1000

120000

92000

0.0001

-28000

-1566000

-424000

150000

-425000 -2028000

25000

11000

-94000 -70000

-5686000

-3621000

347000

82000

1000

10000000

-347000

-81000

4540469

1108374

2250000

11494000

4540469

1108374

1643000

480000

1770000

9851000

4209000

-1932000

15718000

391000

13786000

579000

1000

77000

56000

110000

1000

77000

56000

110000

-19000 -306000 114000 -280000

1168000

599000

1942000

1022000

2111000

1895000

3948000

2645000

3260000

2188000

6004000

3387000

-3259000

-2111000

-5948000

-3277000

5000

-54000

5000

-2000

17000

-3000

35000

10000

36000

-1000

7000

21000

-22000

40000

208000

336000

386000

32000

208000

336000

386000

32000

-3044000

-1754000

-5584000

-3205000

-3252000

-2090000

-0.76

-2.00

-2.21

-3.40

4300073

1043431

2704223

951112

10-Q Yes false 2020-12-31 2021 Q2 Benitec Biopharma Inc. 0001808898 001-39267 --06-30 Yes false true true true CA Common Stock BNTC NASDAQ 4540469

1000

127327000

-108870000

-1864000

16594000

1000

128826000

-116636000

-1953000

856765

1108374

55000

38000

-304000

178000

1720000

186666

-1147000

-2718000

1000

129091000

-109956000

-2168000

16968000

1000

128850000

-119340000

-1775000

7736000

1043431

1108374

1643000

480000

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Business </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Benitec Biopharma Inc. (the “Company”) is a corporation formed under the laws of Delaware, United States of America, on November 22, 2019 and listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BNTC”. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (“BBL”). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April 15, 2020. On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company’s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November 27, 2019, BBL announced its intention to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> acquired all BBL shares and BBL became a wholly-owned subsidiary of Benitec Biopharma Inc.. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL’s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company’s common stock for every three ADSs held. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> was completed on April 15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March 26, 2020 and by the Supreme Court of Queensland on March 30, 2020. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the U.S. Securities and Exchange Commission’s (“SEC”) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company’s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 ratio and share consolidation as if it occurred on July 1, 2019. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The terms the “Company,” “we,” “us,” “our” and similar terms used herein refer (i), prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> to BBL, an Australian corporation, and its subsidiaries, and (ii), following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL). </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s fiscal year end is June 30. References to a particular “fiscal year” are to our fiscal year end June 30 of that calendar year. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:74%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman";;width:13%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principal place of<br/> business/country of<br/> incorporation</div></div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal Year<br/> 2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal Year<br/> 2019</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (“BBL”)</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">Australia</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></div></td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">Australia</td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec Limited</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">United Kingdom</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec, Inc.</div></div></div></td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">USA</td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec LLC</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></div></td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">USA</td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is continuing to monitor the impact of the pandemic of the novel strain of coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“COVID-19”)</div> on all aspects of its business, including how it will impact our employees, suppliers, vendors and business partners. While the Company did experience some disruption from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> including disruption of the timing and completion of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials we are unable to predict the overall impact that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will have on our financial position and operating results due to numerous uncertainties. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:74%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman";;width:13%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principal place of<br/> business/country of<br/> incorporation</div></div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal Year<br/> 2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal Year<br/> 2019</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (“BBL”)</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">Australia</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></div></td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">Australia</td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec Limited</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">United Kingdom</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec, Inc.</div></div></div></td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">USA</td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Benitec LLC</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></div></td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">USA</td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td><td style="vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">% </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1.00

-61000

61000

-14000

14000

14010000

5231000

4570000

538000

861000

16000

69000

7000 18000 1000 1000

562000

949000

1457000

1109000

26000

24000

1518000

1170000

908000

796000

67000

112000

51000

102000

142000 54000

35000

155000

91000

250000

218000

105000

323000

12000

311000

P1Y5M12D

0.0467

shorter of the lease term or estimated useful lives

384676

252516

0.435

0 559162 0 281581 38326 0 29.48 10.50 5.15 0 3.09 0 3.10 82.50 0

70161

444

7967

69717

587296

43273

35473

60.42

69.32

153.78

60.00

7.64

68.53

48.18

145421

DE 780-0819

107095

384676

104000000

52000000

104000000

210000

2019-11-22 one Benitec Biopharma Inc. share for every 300 BBL shares

<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company’s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of SEC Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June 30, 2020. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-size: 12pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted ASC 606 – <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers </div>(“ASC 606”) on July 1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 1: Identify the contract(s) with a customer. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 2: Identify the performance obligations in the contract. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 3: Determine the transaction price. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 4: Allocate the transaction price to the performance obligations in the contract. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Royalties </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company’s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer’s subsequent sales of product occurs. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Services revenue </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P3Y

P4Y

P3Y

P7Y

P3Y

P7Y

P3Y

P5Y

0 0

<div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4. Revenue </div>(US$’000)<div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="margin-bottom: 0px; margin-top: 0px;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></td><td style="vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues from customers</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensing revenue</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">61</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">56</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">61</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">45</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Service revenue*</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">77</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">56</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">110</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;"> </td><td style="text-align:left;;vertical-align:top;;width:5%;">*</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;">On July 9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company’s product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company’s intellectual property related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and the transfer of the right to use the intellectual property of the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June 6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September 3, 2019. The termination discharges all future performance obligations at termination date under the contract. </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div><table cellpadding="0" cellspacing="0" style="width: 92%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width:60.0%; padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended December 31, 2020</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;"> —  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div><table cellpadding="0" cellspacing="0" style="width: 92%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width:60.0%; padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Six Months Ended December 31, 2020</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;"> —  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div><table cellpadding="0" cellspacing="0" style="width: 92%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width:60.0%; padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended December 31, 2019</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;"> —  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">77</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">77</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr style="height:12.0pt"><td style="padding:0in 0in 0in 0in; height:12.0pt"> </td><td colspan="16" style="padding:0in 0in 0in 0in; height:12.0pt"> </td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Six Months Ended December 31, 2019</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">106</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">110</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="margin-bottom: 0px; margin-top: 0px;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></td><td style="vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues from customers</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensing revenue</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">61</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">56</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">61</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">45</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Service revenue*</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">77</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">56</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">110</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;"> </td><td style="text-align:left;;vertical-align:top;;width:5%;">*</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;">On July 9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company’s product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company’s intellectual property related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and the transfer of the right to use the intellectual property of the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June 6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September 3, 2019. The termination discharges all future performance obligations at termination date under the contract. </div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div><table cellpadding="0" cellspacing="0" style="width: 92%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width:60.0%; padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended December 31, 2020</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;"> —  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div><table cellpadding="0" cellspacing="0" style="width: 92%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width:60.0%; padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Six Months Ended December 31, 2020</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;"> —  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div><table cellpadding="0" cellspacing="0" style="width: 92%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width:60.0%; padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="width:7.0%; padding:0in 0in 0in 0in;vertical-align:bottom;"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td><td style="padding:0in 0in 0in 0in"></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended December 31, 2019</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;"> —  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">77</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">77</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:double black 2.25pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr style="height:12.0pt"><td style="padding:0in 0in 0in 0in; height:12.0pt"> </td><td colspan="16" style="padding:0in 0in 0in 0in; height:12.0pt"> </td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="14" style="border:none; border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Six Months Ended December 31, 2019</div></div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="border-bottom:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border:none; margin:0in 0in 0.0001pt; line-height:normal; padding:0in; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue (US$’000)</div></div></div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Licensing</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Royalties</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Development activities</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; border-bottom: 1pt solid white; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:center; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 8pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="padding: 0in; border-bottom: 1pt solid white;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred at a point in time</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">106</div></div></div></td><td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="padding: 0in; font-size: 1pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="border-top:solid black 1.0pt; padding:0in 0in 0in 0in"><div style="border: none; margin: 0px 0in; line-height: normal; padding: 0in; font-family: calibri, sans-serif;"> </div></div></td><td style="padding:0in 0in 0in 0in"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"> </div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap; font-size: 10pt;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:calibri,sans-serif"><div style="display:inline;"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">110</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; line-height: normal; font-family: calibri, sans-serif;"> </div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1000

56000

61000

16000

77000

61000

16000

4000

61000

45000

106000

61000

45000

4000

<div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:78%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:9%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:9%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other receivables</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">21</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"></td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">21</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"></td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6. Trade and other receivables </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:78%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:9%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:9%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other receivables</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">21</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"></td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">21</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"></td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

21000

59000

<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:78%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid expenses</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">538</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">861</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Security deposit</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">69</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other deposit</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market value of listed shares</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total other assets</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">562</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">949</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(210</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current portion</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">352</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">949</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

210000

<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:78%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Trade payable</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">87</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">282</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued license fees</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">142</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">54</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">35</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">155</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other payables</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">91</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">250</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">355</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">741</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

87000

282000

<div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11. Stockholders’ equity </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Common Stock </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October 6, 2020, the Company announced the closing of an underwritten public offering of 2,666,644 shares of its common stock at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the offering price of $3.10 per share. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrants </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On October 6, 2020, the Company announced the closing of an underwritten public offering of 559,162 shares of common stock underlying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“Pre-Funded</div> Warrants”). Of the 559,162 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants issued, 281,581 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants had been exercised as of December 31, 2020. The remaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants may be exercised at any time from issuance. </div><div style="text-indent: 4%; font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to warrants during for the three and six months ended December 31, 2020, is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:73%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Common Stock<br/> from Warrants</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise Price<br/> (per share)</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July 1, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">145,421</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29.48</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(38,326</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">82.50</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at September 30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">107,095</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10.50</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">559,162</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.09</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(281,581</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.10</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at December 31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">384,676</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5.15</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity Incentive Plan </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> the Company assumed BBL’s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> pursuant to the Benitec Officers’ and Employees’ Share Option Plan (the “Share Option Plan”). This includes the Company’s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> no new options have been or will be issued under the Share Option Plan. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity and Incentive Compensation Plan </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December 9, 2020, the Company’s stockholders approved the Company’s 2020 Equity and Incentive Compensation Plan (the “2020 Plan”). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company’s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company’s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Any future equity grants will be made under the 2020 Plan. </div><div style="text-indent: 4%; font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity Awards </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which comprised of stock options during the three and six months ended December 31, 2020, is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:58%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Stock<br/> Options</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/> Remaining<br/> Contractual Term</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June 30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">70,161</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.42</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.89 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(444</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">69.32</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at September 30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">69,717</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.65 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">43,273</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">68.53</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.26 years</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Granted</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">525,546</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.98</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.95 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(7,967</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153.78</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">587,296</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7.64</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">9.2 years</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercisable at December 31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">35,473</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">48.18</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.4 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation Expense </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:74%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> December 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Six Months Ended<br/> December 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"> —  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">76</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">20</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">105</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">92</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation expense</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">82</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">37</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">120</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">92</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, there was $1,393,000 of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. </div></div></div><div style="margin-block: 0em;"> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to warrants during for the three and six months ended December 31, 2020, is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:73%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Common Stock<br/> from Warrants</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise Price<br/> (per share)</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July 1, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">145,421</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29.48</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(38,326</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">82.50</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at September 30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">107,095</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10.50</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">559,162</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.09</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(281,581</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.10</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at December 31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">384,676</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5.15</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which comprised of stock options during the three and six months ended December 31, 2020, is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:58%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Stock<br/> Options</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/> Remaining<br/> Contractual Term</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June 30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">70,161</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.42</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.89 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(444</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">69.32</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at September 30, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">69,717</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.65 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">43,273</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">68.53</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2.26 years</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Granted</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">525,546</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.98</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.95 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(7,967</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153.78</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2020</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">587,296</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7.64</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">9.2 years</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercisable at December 31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">35,473</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">48.18</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.4 years</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:74%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> December 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Six Months Ended<br/> December 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"> —  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">76</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">20</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">105</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">92</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation expense</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">82</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">37</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">120</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">92</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, there was $1,393,000 of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

525546

2.98

true false 3940 Trust Way Hayward 94545 (510)

37000

-319000

319000

336000

-2090000

1043431

1000

128809000

-111727000

-1832000

15251000

281581

82000

-385000

385000

208000

-3252000

4540469

4000

138395000

-122207000

-1567000

50000 50000 3150514 3000 9848000 9851000

-1000

C3 C3 C3 X0 X1 X1 X1 X1 Non-accelerated Filer

0.435

11000

<div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8. Property and equipment, net </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:77%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Software</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,457</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,109</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,518</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,170</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(908</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(796</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">610</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">374</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was $67,000 and $112,000 for the three months and six months ended December 31, 2020, respectively, and $51,000 and $102,000, respectively, for the same periods in 2019. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:77%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Software</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,457</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,109</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,518</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,170</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(908</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(796</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">610</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">374</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);"> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, the Company’s operating lease has a remaining lease term of 1.45 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman";;width:81%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:15%;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$’000)</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">December 31, 2020</td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">105</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">218</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease payments</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">323</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(12</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Present value of operating lease liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">311</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6000

17000

15000

76000

20000

105000

92000

82000

37000

120000

92000

P2Y10M20D

P2Y7M24D

P2Y3M3D

P2Y4M24D

P9Y2M12D

2666644

559162

3.10

3.09

0.01

483870

281581

3.10

1393000

559162

<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company’s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of SEC Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June 30, 2020. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</div> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s functional currency and reporting currency is the United States dollar. BBL’s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translation are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements.</div> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:8%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:6%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:86%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Level 1:</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr><tr style="font-size: 1pt;"><td style="height:8;"> </td><td colspan="2" style="height:8;"> </td><td colspan="2" style="height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Level 2:</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr><tr style="font-size: 1pt;"><td style="height:8;"> </td><td colspan="2" style="height:8;"> </td><td colspan="2" style="height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Level 3:</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company’s cash and cash equivalents, accounts receivables, and accounts payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of December 31, 2020, and June 30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis.</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:10%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:38%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:51%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Software</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Lab equipment</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Furniture and fixtures                </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Computer hardware</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">Leasehold improvements</td><td style="vertical-align:bottom;"> </td><td style="vertical-align:top;">shorter of the lease term or estimated useful lives</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basic and Diluted Net Income (Loss) Per Share </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of December 31, 2020, and 2019, there were 384,676 and 252,516 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive. </div><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted ASC 606 – <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers </div>(“ASC 606”) on July 1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 1: Identify the contract(s) with a customer. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 2: Identify the performance obligations in the contract. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 3: Determine the transaction price. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 4: Allocate the transaction price to the performance obligations in the contract. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Royalties </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company’s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer’s subsequent sales of product occurs. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Services revenue </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Government Research and Development Grants </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant income is generated through the Australian federal government’s Research and Development Tax Incentive program, under which the government provides a cash refund for 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be claiming the Australian Government research and development grants going forward. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="display:inline;">Pre-clinical and clinical development</div> costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records share-based compensation in accordance with ASC 718, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Compensation</div>. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model.</div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted FASB Accounting Standard Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07</div> and accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. </div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting for Income Taxes</div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-13:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments – Credit Losses</div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management’s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (“SRC”) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div> amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s functional currency and reporting currency is the United States dollar. BBL’s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translation are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares

EX-101.SCH 7 bntc-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Business link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Going concern link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Cash and Cash equivalents link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Trade and other receivables link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Other assets link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Property and equipment, net link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Trade and other payables link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Stockholders' equity link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Income taxes link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Commitments and contingencies link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Business (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Cash and Cash equivalents (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Trade and other receivables (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Other assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Property and equipment, net (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Trade and other payables (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Stockholders' equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Business - Summary of entities in control (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Business - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Going concern - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Revenue - Summary of revenue from customers (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Revenue - Summary of disaggregation of revenue (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Trade and other receivables - Summary of trade and other receivables (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Other assets - Summary of other assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Property and equipment, net - Summary of property and equipment net (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Property and equipment, net - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Leases - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Stockholders' equity - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 bntc-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bntc-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bntc-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Document Type Entity Interactive Data Current Entity Interactive Data Current Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Transition Report Document Transition Report Entity Incorporation, State or Country Code Principal place of business/country of incorporation Entity Address, Address Line One City Area Code Local Phone Number Document Quarterly Report Statement of Financial Position [Abstract] Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Other Accrued Liabilities, Current Trade and other payables Total Employee-related Liabilities, Current Accrued employee benefits Operating Lease, Liability, Current Lease liabilities, current portion Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liabilities, less current portion Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 13) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.0001 par value—10,000,000 shares authorized; 4,540,469 and 1,108,374 shares issued and outstanding at December 31, 2020 and June 30, 2020, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Stockholders' Equity Attributable to Parent Total stockholders' equity Balance at the beginning Balance at end Liabilities and Equity Total liabilities and stockholders' equity Assets [Abstract] Assets Operating Lease, Right-of-Use Asset Right-of-use assets Assets Total assets Assets, Current [Abstract] Current assets: Accounts and Other Receivables, Net, Current Trade and other receivables Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Total Other Assets, Current Other current assets Current portion Deposit Assets Deposits Property, Plant and Equipment, Net Property and equipment, net Total property and equipment, net Assets, Current Total current assets Other Assets, Noncurrent Other assets Less: non-current portion Common Stock, Par or Stated Value Per Share Common Stock Par Value Common Stock, Shares Authorized Common Stock Shares Authorized Common Stock, Shares, Issued Common Stock, Shares Issued Common Stock, Shares, Outstanding Common Stock, Shares Outstanding Income Statement [Abstract] Statement [Table] Product and Service [Axis] Product and Service [Domain] Statement [Line Items] Operating Expenses [Abstract] Operating expenses Royalties And License Fees Royalties and license fees Royalties and license fees Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Revenues [Abstract] Revenue: Revenue from Contract with Customer, Including Assessed Tax Revenues from customers Revenues from customers Disaggregated revenue Revenues Total revenues Nonoperating Income (Expense) [Abstract] Other income (loss): Foreign Currency Transaction Gain (Loss), before Tax Foreign currency transaction gain (loss) Interest Income (Expense), Nonoperating, Net Interest income (expense), net Other Nonoperating Income (Expense) Other income, net Unrealized Gain (Loss) on Investments Unrealized loss on investment Unrealized (gain) loss on investment Nonoperating Income (Expense) Total other income (loss), net Earnings Per Share [Abstract] Net loss per share: Earnings Per Share, Basic and Diluted Basic and diluted Net Income (Loss) Attributable to Parent Net loss Net loss Net income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Unrealized foreign currency translation gain Foreign currency translation loss (Gain) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted Equity [Abstract] Equity [Abstract] Class of Stock [Axis] Class of Stock [Domain] Shares, Outstanding Balance at the beginning (In shares) Balance at end (In shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based compensation Stock Issued During Period, Value, New Issues Common stock sold for cash, net of issuance costs of $240 Stock Issued During Period, Shares, New Issues Common stock sold for cash, net of issuance costs of $240, Shares Issuance and exercise of prefunded warrants Issuance of pre-funded warrants, net of transaction costs of $240, Shares Issuance and exercise of pre-funded warrants. Shares Issued, Value, Share-based Payment Arrangement, Forfeited Forfeiture of share-based payments Issuance And Exercise Of Prefunded Warrants Net Of Transaction Costs Issuance of pre-funded warrants, net of transaction costs of $240 Issuance and exercise of pre-funded warrants, net of transaction costs. Warrants Exercised During The Period Exercise of pre-funded warrants, Shares Warrants exercised during the period. Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Payments of Stock Issuance Costs Payments For Stock Issuance Costs Shares and pre-funded warrant issuance costs Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts and Other Receivables Trade and other receivables Increase (Decrease) in Other Operating Assets Other assets Increase Decrease in Accounts and Other Payables Trade and other payables Increase (decrease) in accounts and other payables. Increase (Decrease) in Employee Related Liabilities Accrued employee benefits Increase Decrease In Lease Liabilities Lease liabilities Increase decrease In lease liabilities. Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amortization of Right of Use Assets Amortization of right-of-use assets Amortization of right-of-use assets. Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of fixed assets Share-based Payment Arrangement, Noncash Expense Share-based compensation expense Depreciation, Depletion and Amortization Depreciation and amortization Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in provided by operations Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from disposal of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issues of shares and pre-funded warrants Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow information: Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Initial measurement of operating lease right-of-use assets and liabilities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Effects of exchange rate changes on cash and cash equivalents Schedule Of Entities In Control [Abstract] Business Description and Basis of Presentation [Text Block] Business Accounting Policies [Abstract] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Basis of presentation and summary of significant accounting policies Going Concern [Abstract] Going concern Going Concern Disclosure [Text Block] Going concern Going concern disclosure. Revenue from Contract with Customer [Text Block] Revenue Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Disclosure [Text Block] Cash and cash equivalents Receivables [Abstract] Trade and other receivables disclosure [Text Block] Trade and other receivables Trade and other receivables disclosure Other Assets [Abstract] Other Assets Disclosure [Text Block] Other assets Property, Plant and Equipment, Net [Abstract] Property and equipment, net Property, Plant and Equipment Disclosure [Text Block] Property and equipment, net Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Trade and other payables Leases [Abstract] Lessee, Operating Leases [Text Block] Leases Stockholders' Equity Note Disclosure [Text Block] Stockholders' equity Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Consolidation, Policy [Policy Text Block] Principles of Consolidation Segment Reporting, Policy [Policy Text Block] Segment Reporting Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation and Other Comprehensive Income (Loss) Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Revenue [Policy Text Block] Revenue Recognition Government Research and Development Grants [Policy Text Block] Government Research and Development Grants Government Research and Development Grants. Research and Development Expense, Policy [Policy Text Block] Research and Development Expense Share-based Payment Arrangement [Policy Text Block] Equity-based Compensation Expense Income Tax, Policy [Policy Text Block] Income Taxes Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Risk Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block] Trade and Other Receivables Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Trade and other payables [Policy Text Block] Trade and other payables Trade and other payables. Earnings Per Share, Policy [Policy Text Block] Basic and Diluted Net Income (Loss) Per Share Lessee, Leases [Policy Text Block] Leases New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Schedule Of Entities In Control [Table Text Block] Summary of entities in control Schedule of entities in control. Revenue from External Customers by Products and Services [Table Text Block] Summary of revenue from customers Disaggregation of Revenue [Table Text Block] Summary of disaggregation of revenue Schedule of Cash and Cash Equivalents [Table Text Block] Summary of cash and cash equivalent Schedule of Trade and other receivables [Table Text Block] Summary of trade and other receivables Schedule of trade and other receivables. Schedule of Other Assets [Table Text Block] Summary of other assets Property, Plant and Equipment [Table Text Block] Summary of property and equipment net Schedule of Accrued Liabilities [Table Text Block] Summary of trade and other payables Lessee, Operating Lease, Liability, Maturity [Table Text Block] Summary of maturities of the operating lease liabilities Share-based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of share-basedcompensation expense Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of equity awards Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrants or rights EX-101.PRE 11 bntc-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	6 Months Ended
Cover Page - shares	Dec. 31, 2020	Feb. 04, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39267
Entity Registrant Name	Benitec Biopharma Inc.
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001808898
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3940 Trust Way Hayward
Entity Address, Country	CA
Entity Address, Postal Zip Code	94545
City Area Code	(510)
Local Phone Number	780-0819
Title of 12(b) Security	Common Stock
Trading Symbol	BNTC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		4,540,469

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 14,010	$ 9,801
Trade and other receivables	21	59
Other current assets	352	949
Total current assets	14,383	10,809
Property and equipment, net	610	374
Deposits	9	9
Other assets	210
Right-of-use assets	300	395
Total assets	15,512	11,587
Current liabilities:
Trade and other payables	355	741
Accrued employee benefits	221	203
Lease liabilities, current portion	203	192
Total current liabilities	779	1,136
Lease liabilities, less current portion	108	213
Total liabilities	887	1,349
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.0001 par value—10,000,000 shares authorized; 4,540,469 and 1,108,374 shares issued and outstanding at December 31, 2020 and June 30, 2020, respectively	4	1
Additional paid-in capital	138,395	128,826
Accumulated deficit	(122,207)	(116,636)
Accumulated other comprehensive loss	(1,567)	(1,953)
Total stockholders' equity	14,625	10,238
Total liabilities and stockholders' equity	$ 15,512	$ 11,587

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Jun. 30, 2020
Statement of Financial Position [Abstract]
Common Stock Par Value	$ 0.0001	$ 0.0001
Common Stock Shares Authorized	10,000,000	10,000,000
Common Stock, Shares Issued	4,540,469	1,108,374
Common Stock, Shares Outstanding	4,540,469	1,108,374

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Revenues from customers	$ 1	$ 77	$ 56	$ 110
Total revenues	1	77	56	110
Operating expenses
Royalties and license fees	(19)	(306)	114	(280)
Research and development	1,168	599	1,942	1,022
General and administrative	2,111	1,895	3,948	2,645
Total operating expenses	3,260	2,188	6,004	3,387
Loss from operations	(3,259)	(2,111)	(5,948)	(3,277)
Other income (loss):
Foreign currency transaction gain (loss)		5	(54)	5
Interest income (expense), net	(2)	17	(3)	35
Other income, net	10		36
Unrealized loss on investment	(1)	(1)	(1)	(1)
Total other income (loss), net	7	21	(22)	40
Net loss	(3,252)	(2,090)	(5,970)	(3,237)
Other comprehensive income:
Unrealized foreign currency translation gain	208	336	386	32
Total other comprehensive income	208	336	386	32
Total comprehensive loss	$ (3,044)	$ (1,754)	$ (5,584)	$ (3,205)
Net loss per share:
Basic and diluted	$ (0.76)	$ (2.00)	$ (2.21)	$ (3.40)
Weighted average number of shares outstanding:
Basic and diluted	4,300,073	1,043,431	2,704,223	951,112

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at the beginning at Jun. 30, 2019	$ 16,594	$ 1	$ 127,327	$ (108,870)	$ (1,864)
Balance at the beginning (In shares) at Jun. 30, 2019		856,765
Common stock sold for cash, net of issuance costs of $240	1,720		1,720
Common stock sold for cash, net of issuance costs of $240, Shares		186,666
Issuance of pre-funded warrants, net of transaction costs of $240	50		50
Share-based compensation	55		55
Forfeiture of share-based payments			(61)	61
Foreign currency translation loss (Gain)	(304)				(304)
Net loss	(1,147)			(1,147)
Balance at end (In shares) at Sep. 30, 2019		1,043,431
Balance at end at Sep. 30, 2019	16,968	$ 1	129,091	(109,956)	(2,168)
Balance at the beginning at Jun. 30, 2019	16,594	$ 1	127,327	(108,870)	(1,864)
Balance at the beginning (In shares) at Jun. 30, 2019		856,765
Foreign currency translation loss (Gain)	32
Net loss	(3,237)
Balance at end (In shares) at Dec. 31, 2019		1,043,431
Balance at end at Dec. 31, 2019	15,251	$ 1	128,809	(111,727)	(1,832)
Balance at the beginning at Sep. 30, 2019	16,968	$ 1	129,091	(109,956)	(2,168)
Balance at the beginning (In shares) at Sep. 30, 2019		1,043,431
Share-based compensation	37		37
Forfeiture of share-based payments			(319)	319
Foreign currency translation loss (Gain)	336				336
Net loss	(2,090)			(2,090)
Balance at end (In shares) at Dec. 31, 2019		1,043,431
Balance at end at Dec. 31, 2019	15,251	$ 1	128,809	(111,727)	(1,832)
Balance at the beginning at Jun. 30, 2020	10,238	$ 1	128,826	(116,636)	(1,953)
Balance at the beginning (In shares) at Jun. 30, 2020		1,108,374
Share-based compensation	38		38
Forfeiture of share-based payments			(14)	14
Foreign currency translation loss (Gain)	178				178
Net loss	(2,718)			(2,718)
Balance at end (In shares) at Sep. 30, 2020		1,108,374
Balance at end at Sep. 30, 2020	7,736	$ 1	128,850	(119,340)	(1,775)
Balance at the beginning at Jun. 30, 2020	10,238	$ 1	128,826	(116,636)	(1,953)
Balance at the beginning (In shares) at Jun. 30, 2020		1,108,374
Foreign currency translation loss (Gain)	386
Net loss	(5,970)
Balance at end (In shares) at Dec. 31, 2020		4,540,469
Balance at end at Dec. 31, 2020	14,625	$ 4	138,395	(122,207)	(1,567)
Balance at the beginning at Sep. 30, 2020	7,736	$ 1	128,850	(119,340)	(1,775)
Balance at the beginning (In shares) at Sep. 30, 2020		1,108,374
Issuance of pre-funded warrants, net of transaction costs of $240	9,851	$ 3	9,848
Issuance of pre-funded warrants, net of transaction costs of $240, Shares		3,150,514
Exercise of pre-funded warrants, Shares		281,581
Share-based compensation	82		82
Forfeiture of share-based payments			(385)	385
Foreign currency translation loss (Gain)	208				208
Net loss	(3,252)			(3,252)
Balance at end (In shares) at Dec. 31, 2020		4,540,469
Balance at end at Dec. 31, 2020	$ 14,625	$ 4	$ 138,395	$ (122,207)	$ (1,567)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Payments For Stock Issuance Costs	$ 1,643	$ 480	$ 1,643	$ 480

XML 18 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (5,970)	$ (3,237)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	112	102
Amortization of right-of-use assets	95	91
Loss on disposal of fixed assets		1
Unrealized (gain) loss on investment	1	1
Share-based compensation expense	120	92
Changes in operating assets and liabilities:
Trade and other receivables	28	1,566
Other assets	424	(150)
Trade and other payables	(425)	(2,028)
Accrued employee benefits	25	11
Lease liabilities	(94)	(70)
Net cash used in operating activities	(5,686)	(3,621)
Cash flows from investing activities:
Purchases of property and equipment	(347)	(82)
Proceeds from disposal of property and equipment		1
Net cash used in investing activities	(347)	(81)
Cash flows from financing activities:
Proceeds from issues of shares and pre-funded warrants	11,494	2,250
Shares and pre-funded warrant issuance costs	(1,643)	(480)
Net cash provided by financing activities	9,851	1,770
Effects of exchange rate changes on cash and cash equivalents	391
Net increase (decrease) in cash and cash equivalents	4,209	(1,932)
Cash and cash equivalents, beginning of period	9,801	15,718
Cash and cash equivalents, end of period	$ 14,010	13,786
Supplemental disclosure of cash flow information:
Initial measurement of operating lease right-of-use assets and liabilities		$ (579)

XML 19 R8.htm IDEA: XBRL DOCUMENT

Business

6 Months Ended

Dec. 31, 2020

Schedule Of Entities In Control [Abstract]

Business

1. Business

DNA-directed

RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes.

On November 27, 2019, BBL announced its intention to

re-domicile

from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the

re-domiciliation,

acquired all BBL shares and BBL became a wholly-owned subsidiary of Benitec Biopharma Inc.. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL’s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company’s common stock for every three ADSs held. The

re-domiciliation

was completed on April 15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March 26, 2020 and by the Supreme Court of Queensland on March 30, 2020.

The terms the “Company,” “we,” “us,” “our” and similar terms used herein refer (i), prior to the

re-domiciliation

to BBL, an Australian corporation, and its subsidiaries, and (ii), following the

re-domiciliation,

to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).

The Company’s fiscal year end is June 30. References to a particular “fiscal year” are to our fiscal year end June 30 of that calendar year.

The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:


	Principal place of business/country of incorporation	Ownership Fiscal Year 2020			Ownership Fiscal Year 2019
Benitec Biopharma Proprietary Limited (“BBL”)	Australia		100	%		—
Benitec Australia Proprietary Limited	Australia		100	%		100	%
Benitec Limited	United Kingdom		100	%		100	%
Benitec, Inc.	USA		100	%		100	%
Benitec LLC	USA		100	%		100	%
RNAi Therapeutics, Inc.	USA		100	%		100	%
Tacere Therapeutics, Inc.	USA		100	%		100	%

The Company is continuing to monitor the impact of the pandemic of the novel strain of coronavirus

COVID-19

(“COVID-19”)

on all aspects of its business, including how it will impact our employees, suppliers, vendors and business partners. While the Company did experience some disruption from

COVID-19

including disruption of the timing and completion of certain

pre-clinical

trials we are unable to predict the overall impact that

COVID-19

will have on our financial position and operating results due to numerous uncertainties.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies

6 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of presentation and summary of significant accounting policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The Company’s consolidated financial statements contained in this Quarterly Report on Form

10-Q

have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form

10-Q

and Article 10 of SEC Regulation

S-X.

Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Company’s Annual Report on Form

10-K

for the year ended June 30, 2020.

non-governmental

entities.

Principles of Consolidation

The consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

right-of-use

asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Segment Reporting

Foreign Currency Translation and Other Comprehensive Income (Loss)

Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).

Fair Value Measurements

The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820,

Fair Value Measurements.

For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities.


		Level 1:		Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

		Level 2:		Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

		Level 3:		Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

Cash and Cash Equivalents

Concentrations of Risk

Trade and Other Receivables

write-off

experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.

Property and Equipment


		Software		3-4 years
		Lab equipment		3-7 years
		Furniture and fixtures		3-7 years
		Computer hardware		3-5 years
		Leasehold improvements		shorter of the lease term or estimated useful lives

Impairment of Long-Lived Assets

Trade and other payables

Leases

right-of-use

lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.

right-of-use

lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.

Basic and Diluted Net Income (Loss) Per Share

Revenue Recognition

The Company adopted ASC 606 –

Revenue from Contracts with Customers

(“ASC 606”) on July 1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements.

Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Management has also made the judgement that the grant of the license and transfer of associated

know-how

and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and

know-how

and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of

know-how

has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.

Licensing revenues

Royalties

Services revenue

Government Research and Development Grants

The Company will not be claiming the Australian Government research and development grants going forward.

Research and Development Expense

pre-clinical

trials.

Pre-clinical and clinical development

costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.

Equity-based Compensation Expense

The Company records share-based compensation in accordance with ASC 718,

Stock Compensation

. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and

non-employee

share-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company adopted FASB Accounting Standard Update (“ASU”)

2018-07

and accounts for

non-employee

share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.

Income Taxes

The Company is governed by Australia and United States income tax laws. The Company follows ASC 740

Accounting for Income Taxes

, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU

No. 2016-13:

Financial Instruments – Credit Losses

(Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management’s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (“SRC”) as of November 15, 2019. As such, ASU

2019-10:

Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates

amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Going concern

6 Months Ended

Dec. 31, 2020

Going Concern [Abstract]

Going concern

3. Going Concern

XML 22 R11.htm IDEA: XBRL DOCUMENT

Revenue

6 Months Ended

Dec. 31, 2020

Revenues [Abstract]

Revenue

4. Revenue

(US$’000)


	Three Months Ended				Six Months Ended
Revenues from customers	December 31, 2020		December 31, 2019		December 31, 2020		December 31, 2019
Licensing revenue	$	1	$	61	$	56	$	61
Royalty revenue		—		16		—		45
Service revenue*		—		—		—		4

Total	$	1	$	77	$	56	$	110

BB-301,

which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company’s intellectual property related to

BB-301

and the transfer of the right to use the intellectual property of the Company’s

BB-301

license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June 6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September 3, 2019. The termination discharges all future performance obligations at termination date under the contract.


	Three Months Ended December 31, 2020
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		1		—		—		1

Total	$	1	$	—	$	—	$	1


	Six Months Ended December 31, 2020
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		56		—		—		56

Total	$	56	$	—	$	—	$	56


	Three Months Ended December 31, 2019
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		61		16		—		77

Total	$	61	$	16	$	—	$	77


	Six Months Ended December 31, 2019
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	4	$	4
Services transferred over time		61		45		—		106

Total	$	61	$	45	$	4	$	110

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Cash and Cash equivalents

6 Months Ended

Dec. 31, 2020

Cash and Cash Equivalents [Abstract]

Cash and cash equivalents

5. Cash and Cash equivalents


(US$’000)	December 31, 2020		June 30, 2020
Cash at Bank	$	14,010	$	5,231
Term Deposit		—		4,570

Total	$	14,010	$	9,801

XML 24 R13.htm IDEA: XBRL DOCUMENT

Trade and other receivables

6 Months Ended

Dec. 31, 2020

Receivables [Abstract]

Trade and other receivables

6. Trade and other receivables


(US$’000)	December 31, 2020		June 30, 2020
Other receivables	$	21	$	59

Total	$	21	$	59

XML 25 R14.htm IDEA: XBRL DOCUMENT

Other assets

6 Months Ended

Dec. 31, 2020

Other Assets [Abstract]

Other assets

7. Other assets


(US$’000)	December 31, 2020			June 30, 2020
Prepaid expenses	$	538		$	861
Security deposit		16			69
Other deposit		7			18
Market value of listed shares		1			1

Total other assets		562			949
Less: non-current portion		(210	)		—

Current portion	$	352		$	949

XML 26 R15.htm IDEA: XBRL DOCUMENT

Property and equipment, net

6 Months Ended

Dec. 31, 2020

Property, Plant and Equipment, Net [Abstract]

Property and equipment, net

8. Property and equipment, net


(US$’000)	December 31, 2020			June 30, 2020
Software	$	11		$	11
Lab equipment		1,457			1,109
Computer hardware		26			26
Leasehold improvements		24			24

Total property and equipment, gross		1,518			1,170
Accumulated depreciation and amortization		(908	)		(796	)

Total property and equipment, net	$	610		$	374

Depreciation expense was $67,000 and $112,000 for the three months and six months ended December 31, 2020, respectively, and $51,000 and $102,000, respectively, for the same periods in 2019.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Trade and other payables

6 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Trade and other payables

9. Trade and other payables


(US$’000)	December 31, 2020		June 30, 2020
Trade payable	$	87	$	282
Accrued license fees		142		54
Accrued professional fees		35		155
Other payables		91		250

Total	$	355	$	741

XML 28 R17.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Dec. 31, 2020

Leases [Abstract]

Leases

10. Leases

As of December 31, 2020, the Company’s operating lease has a remaining lease term of 1.45 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows:


(US$’000)	December 31, 2020
2021	$	105
2022		218

Total operating lease payments		323
Less imputed interest		(12	)

Present value of operating lease liabilities	$	311

The Company recorded lease liabilities and

right-of-use

lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company’s incremental borrowing rate. Rent expense was $52,000 and $104,000 for the three months and six months ended December 31, 2020, respectively, and $52,000 and $104,000, respectively, for the same periods in 2019.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stockholders' equity

6 Months Ended

Dec. 31, 2020

Equity [Abstract]

Stockholders' equity

11. Stockholders’ equity

Common Stock

Warrants

On October 6, 2020, the Company announced the closing of an underwritten public offering of 559,162 shares of common stock underlying

pre-funded

warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share

(“Pre-Funded

Warrants”). Of the 559,162

Pre-Funded

Warrants issued, 281,581

Pre-Funded

Warrants had been exercised as of December 31, 2020. The remaining

Pre-Funded

Warrants may be exercised at any time from issuance.

The activity related to warrants during for the three and six months ended December 31, 2020, is summarized as follows:


	Common Stock from Warrants			Weighted- average Exercise Price (per share)
Outstanding at July 1, 2020		145,421		$	29.48
Granted		—			—
Exercised		—			—
Forfeited		(38,326	)		82.50
Outstanding and exercisable at September 30, 2020		107,095		$	10.50
Granted		559,162			3.09
Exercised		(281,581	)		3.10
Forfeited		—			—
Outstanding and exercisable at December 31, 2020		384,676		$	5.15

Equity Incentive Plan

Employee Share Option Plan

Upon the

re-domiciliation,

the Company assumed BBL’s obligations with respect to the settlement of options that were issued by BBL prior to the

re-domiciliation

pursuant to the Benitec Officers’ and Employees’ Share Option Plan (the “Share Option Plan”). This includes the Company’s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. After the

re-domiciliation,

no new options have been or will be issued under the Share Option Plan.

Equity and Incentive Compensation Plan

one-third

on each anniversary of the applicable grant date for three years.

Non-employee

director options vest in increments of

one-third

on the day prior to each of the Company’s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Any future equity grants will be made under the 2020 Plan.

Equity Awards

The activity related to equity awards, which comprised of stock options during the three and six months ended December 31, 2020, is summarized as follows:


	Stock Options			Weighted- average Exercise Price		Weighted-average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at June 30, 2020		70,161		$	60.42		2.89 years	$	—
Granted		—			—
Exercised		—			—
Forfeited		(444	)		69.32

Outstanding at September 30, 2020		69,717		$	60.00		2.65 years		—
Exercisable at September 30, 2020		43,273		$	68.53		2.26 years	$	—

Granted		525,546			2.98		9.95 years
Exercised		—			—
Forfeited		(7,967	)		153.78

Outstanding at December 31, 2020		587,296			7.64		9.2 years		—
Exercisable at December 31, 2020		35,473		$	48.18		2.4 years	$	—

Share-Based Compensation Expense

The classification of share-based compensation expense is summarized as follows:


	Three Months Ended December 31,				Six Months Ended December 31,
(US$’000)	2020		2019		2020		2019
Research and development	$	6	$	17	$	15	$	—
General and administrative		76		20		105		92

Total share-based compensation expense	$	82	$	37	$	120	$	92

As of December 31, 2020, there was $1,393,000 of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Income taxes

6 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income taxes

12. Income taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Commitments and contingencies

6 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

13. Commitments and contingencies

Contract commitments

Contingencies

XML 32 R21.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

6 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation

The Company’s consolidated financial statements contained in this Quarterly Report on Form

10-Q

have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form

10-Q

and Article 10 of SEC Regulation

S-X.

10-K

for the year ended June 30, 2020.

non-governmental

entities.

Principles of Consolidation

The consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

right-of-use

Segment Reporting

Foreign Currency Translation and Other Comprehensive Income (Loss)

Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).

Fair Value Measurements

The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820,

Fair Value Measurements.

For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities.


		Level 1:		Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

		Level 2:		Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

		Level 3:		Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

Cash and Cash Equivalents

Concentrations of Risk

Trade and Other Receivables

write-off

experience. The Company’s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.

Property and Equipment


		Software		3-4 years
		Lab equipment		3-7 years
		Furniture and fixtures		3-7 years
		Computer hardware		3-5 years
		Leasehold improvements		shorter of the lease term or estimated useful lives

Impairment of Long-Lived Assets

Trade and other payables

Leases

right-of-use

lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.

right-of-use

Basic and Diluted Net Income (Loss) Per Share

Revenue Recognition

The Company adopted ASC 606 –

Revenue from Contracts with Customers

(“ASC 606”) on July 1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements.

Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

Management has also made the judgement that the grant of the license and transfer of associated

know-how

and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of

know-how

has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.

Licensing revenues

Royalties

Services revenue

Government Research and Development Grants

The Company will not be claiming the Australian Government research and development grants going forward.

Research and Development Expense

pre-clinical

trials.

Pre-clinical and clinical development

Equity-based Compensation Expense

The Company records share-based compensation in accordance with ASC 718,

Stock Compensation

non-employee

share-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company adopted FASB Accounting Standard Update (“ASU”)

2018-07

and accounts for

non-employee

share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.

Income Taxes

The Company is governed by Australia and United States income tax laws. The Company follows ASC 740

Accounting for Income Taxes

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU

No. 2016-13:

Financial Instruments – Credit Losses

2019-10:

Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates

amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Business (Tables)

6 Months Ended

Dec. 31, 2020

Schedule Of Entities In Control [Abstract]

Summary of entities in control

The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:


	Principal place of business/country of incorporation	Ownership Fiscal Year 2020			Ownership Fiscal Year 2019
Benitec Biopharma Proprietary Limited (“BBL”)	Australia		100	%		—
Benitec Australia Proprietary Limited	Australia		100	%		100	%
Benitec Limited	United Kingdom		100	%		100	%
Benitec, Inc.	USA		100	%		100	%
Benitec LLC	USA		100	%		100	%
RNAi Therapeutics, Inc.	USA		100	%		100	%
Tacere Therapeutics, Inc.	USA		100	%		100	%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

6 Months Ended

Dec. 31, 2020

Revenues [Abstract]

Summary of revenue from customers


	Three Months Ended				Six Months Ended
Revenues from customers	December 31, 2020		December 31, 2019		December 31, 2020		December 31, 2019
Licensing revenue	$	1	$	61	$	56	$	61
Royalty revenue		—		16		—		45
Service revenue*		—		—		—		4

Total	$	1	$	77	$	56	$	110

BB-301,

which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company’s intellectual property related to

BB-301

and the transfer of the right to use the intellectual property of the Company’s

BB-301

Summary of disaggregation of revenue


	Three Months Ended December 31, 2020
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		1		—		—		1

Total	$	1	$	—	$	—	$	1


	Six Months Ended December 31, 2020
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		56		—		—		56

Total	$	56	$	—	$	—	$	56


	Three Months Ended December 31, 2019
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		61		16		—		77

Total	$	61	$	16	$	—	$	77


	Six Months Ended December 31, 2019
Disaggregated revenue (US$’000)	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	4	$	4
Services transferred over time		61		45		—		106

Total	$	61	$	45	$	4	$	110

XML 35 R24.htm IDEA: XBRL DOCUMENT

Cash and Cash equivalents (Tables)

6 Months Ended

Dec. 31, 2020

Cash and Cash Equivalents [Abstract]

Summary of cash and cash equivalent


(US$’000)	December 31, 2020		June 30, 2020
Cash at Bank	$	14,010	$	5,231
Term Deposit		—		4,570

Total	$	14,010	$	9,801

XML 36 R25.htm IDEA: XBRL DOCUMENT

Trade and other receivables (Tables)

6 Months Ended

Dec. 31, 2020

Receivables [Abstract]

Summary of trade and other receivables


(US$’000)	December 31, 2020		June 30, 2020
Other receivables	$	21	$	59

Total	$	21	$	59

XML 37 R26.htm IDEA: XBRL DOCUMENT

Other assets (Tables)

6 Months Ended

Dec. 31, 2020

Other Assets [Abstract]

Summary of other assets


(US$’000)	December 31, 2020			June 30, 2020
Prepaid expenses	$	538		$	861
Security deposit		16			69
Other deposit		7			18
Market value of listed shares		1			1

Total other assets		562			949
Less: non-current portion		(210	)		—

Current portion	$	352		$	949

XML 38 R27.htm IDEA: XBRL DOCUMENT

Property and equipment, net (Tables)

6 Months Ended

Dec. 31, 2020

Property, Plant and Equipment, Net [Abstract]

Summary of property and equipment net


(US$’000)	December 31, 2020			June 30, 2020
Software	$	11		$	11
Lab equipment		1,457			1,109
Computer hardware		26			26
Leasehold improvements		24			24

Total property and equipment, gross		1,518			1,170
Accumulated depreciation and amortization		(908	)		(796	)

Total property and equipment, net	$	610		$	374

XML 39 R28.htm IDEA: XBRL DOCUMENT

Trade and other payables (Tables)

6 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Summary of trade and other payables


(US$’000)	December 31, 2020		June 30, 2020
Trade payable	$	87	$	282
Accrued license fees		142		54
Accrued professional fees		35		155
Other payables		91		250

Total	$	355	$	741

XML 40 R29.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Dec. 31, 2020

Leases [Abstract]

Summary of maturities of the operating lease liabilities

As of December 31, 2020, the Company’s operating lease has a remaining lease term of 1.45 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows:


(US$’000)	December 31, 2020
2021	$	105
2022		218

Total operating lease payments		323
Less imputed interest		(12	)

Present value of operating lease liabilities	$	311

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stockholders' equity (Tables)

6 Months Ended

Dec. 31, 2020

Equity [Abstract]

Schedule of warrants or rights

The activity related to warrants during for the three and six months ended December 31, 2020, is summarized as follows:


	Common Stock from Warrants			Weighted- average Exercise Price (per share)
Outstanding at July 1, 2020		145,421		$	29.48
Granted		—			—
Exercised		—			—
Forfeited		(38,326	)		82.50
Outstanding and exercisable at September 30, 2020		107,095		$	10.50
Granted		559,162			3.09
Exercised		(281,581	)		3.10
Forfeited		—			—
Outstanding and exercisable at December 31, 2020		384,676		$	5.15

Schedule of equity awards

The activity related to equity awards, which comprised of stock options during the three and six months ended December 31, 2020, is summarized as follows:


	Stock Options			Weighted- average Exercise Price		Weighted-average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at June 30, 2020		70,161		$	60.42		2.89 years	$	—
Granted		—			—
Exercised		—			—
Forfeited		(444	)		69.32

Outstanding at September 30, 2020		69,717		$	60.00		2.65 years		—
Exercisable at September 30, 2020		43,273		$	68.53		2.26 years	$	—

Granted		525,546			2.98		9.95 years
Exercised		—			—
Forfeited		(7,967	)		153.78

Outstanding at December 31, 2020		587,296			7.64		9.2 years		—
Exercisable at December 31, 2020		35,473		$	48.18		2.4 years	$	—

Schedule of share-basedcompensation expense

The classification of share-based compensation expense is summarized as follows:


	Three Months Ended December 31,				Six Months Ended December 31,
(US$’000)	2020		2019		2020		2019
Research and development	$	6	$	17	$	15	$	—
General and administrative		76		20		105		92

Total share-based compensation expense	$	82	$	37	$	120	$	92

As of December 31, 2020, there was $1,393,000 of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan.

XML 42 R31.htm IDEA: XBRL DOCUMENT

Business - Summary of entities in control (Detail)	6 Months Ended
Business - Summary of entities in control (Detail)	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	DE
Benitec Biopharma Proprietary Limited ("BBL") [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	C3
Equity method investment, ownership percentage	100.00%
Benitec Australia Proprietary Limited [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	C3
Equity method investment, ownership percentage	100.00%	100.00%
Benitec Limited [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X0
Equity method investment, ownership percentage	100.00%	100.00%
Benitec, Inc. [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Equity method investment, ownership percentage	100.00%	100.00%
Benitec LLC [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Equity method investment, ownership percentage	100.00%	100.00%
RNAi Therapeutics, Inc. [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Equity method investment, ownership percentage	100.00%	100.00%
Tacere Therapeutics, Inc. [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	X1
Equity method investment, ownership percentage	100.00%	100.00%
Benitec Biopharma Proprietary Limited [Member]
Schedule Of Entities In Control [Line Items]
Principal place of business/country of incorporation	C3

XML 43 R32.htm IDEA: XBRL DOCUMENT

Business - Additional information (Detail)		6 Months Ended
Business - Additional information (Detail)	Nov. 27, 2019	Dec. 31, 2020
Schedule Of Entities In Control [Abstract]
Entity Incorporation Date Of Incorporation		Nov. 22, 2019
Common Stock, Shares, Re-domiciliation Description	one Benitec Biopharma Inc. share for every 300 BBL shares

XML 44 R33.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)	6 Months Ended
	Dec. 31, 2020
Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Lab equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Furniture and fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Computer hardware [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer hardware [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	shorter of the lease term or estimated useful lives

XML 45 R34.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) - USD ($)	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from the computation of earnings per share	384,676	252,516
Grant Receivable on research and development expenditures [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	43.50%	43.50%
Fair Value, Recurring [Member]
Summary Of Significant Accounting Policies [Line Items]
Financial assets at fair value	$ 0		$ 0
Financial liabilities at fair value	$ 0		$ 0

XML 46 R35.htm IDEA: XBRL DOCUMENT

Going concern - Additional information (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Going Concern [Abstract]
Net income (loss)	$ (3,252)	$ (2,718)	$ (2,090)	$ (1,147)	$ (5,970)	$ (3,237)
Net cash used in provided by operations					(5,686)	(3,621)
Cash and cash equivalents	$ 14,010		$ 13,786		$ 14,010	$ 13,786	$ 9,801	$ 15,718

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 47 R36.htm IDEA: XBRL DOCUMENT

Revenue - Summary of revenue from customers (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenue from External Customer [Line Items]
Revenues from customers	$ 1	$ 77	$ 56	$ 110
Licensing revenue [Member]
Revenue from External Customer [Line Items]
Revenues from customers	1	61	56	61
Royalty revenue [Member]
Revenue from External Customer [Line Items]
Revenues from customers	0	16	0	45
Service revenue [Member]
Revenue from External Customer [Line Items]
Revenues from customers	$ 0	$ 0	$ 0	$ 4

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 48 R37.htm IDEA: XBRL DOCUMENT

Revenue - Summary of disaggregation of revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Disaggregated revenue	$ 1	$ 77	$ 56	$ 110
License [Member]
Disaggregated revenue	1	61	56	61
Royalty [Member]
Disaggregated revenue	0	16	0	45
Development Activities [Member]
Disaggregated revenue	0	0	0	4
Services transferred at a point in time [Member]
Disaggregated revenue				4
Services transferred at a point in time [Member] \| Development Activities [Member]
Disaggregated revenue				4
Services transferred over time [Member]
Disaggregated revenue	1	77	56	106
Services transferred over time [Member] \| License [Member]
Disaggregated revenue	$ 1	61	$ 56	61
Services transferred over time [Member] \| Royalty [Member]
Disaggregated revenue		$ 16		$ 45

- Definition

+ References

+ Details

XML 49 R38.htm IDEA: XBRL DOCUMENT

Cash and Cash equivalents - Summary of cash and cash equivalent (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Cash and Cash Equivalents [Abstract]
Cash at Bank	$ 14,010	$ 5,231
Term Deposit	0	4,570
Total	$ 14,010	$ 9,801	$ 13,786	$ 15,718

XML 50 R39.htm IDEA: XBRL DOCUMENT

Trade and other receivables - Summary of trade and other receivables (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Receivables [Abstract]
Other receivables	$ 21	$ 59
Total	$ 21	$ 59

XML 51 R40.htm IDEA: XBRL DOCUMENT

Other assets - Summary of other assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Other Assets [Abstract]
Prepaid expenses	$ 538	$ 861
Security deposit	16	69
Other deposit	7	18
Market value of listed shares	1	1
Total other assets	562	949
Less: non-current portion	(210)
Current portion	$ 352	$ 949

XML 52 R41.htm IDEA: XBRL DOCUMENT

Property and equipment, net - Summary of property and equipment net (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 1,518	$ 1,170
Accumulated depreciation and amortization	(908)	(796)
Total property and equipment, net	610	374
Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	11	11
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,457	1,109
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	26	26
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 24	$ 24

XML 53 R42.htm IDEA: XBRL DOCUMENT

Property and equipment, net - Additional information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Net [Abstract]
Depreciation	$ 67,000	$ 51,000	$ 112,000	$ 102,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

Trade and other payables- Summary of trade and other payables (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Payables and Accruals [Abstract]
Trade payable	$ 87	$ 282
Accrued license fees	142	54
Accrued professional fees	35	155
Other payables	91	250
Total	$ 355	$ 741

XML 55 R44.htm IDEA: XBRL DOCUMENT

Leases - Summary of maturities of the operating lease liabilities (Detail) $ in Thousands	Dec. 31, 2020 USD ($)
Leases [Abstract]
2021	$ 105
2022	218
Total operating lease payments	323
Less imputed interest	(12)
Present value of operating lease liabilities	$ 311

XML 56 R45.htm IDEA: XBRL DOCUMENT

Leases - Additional information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Operating lease has a remaining lease term	1 year 5 months 12 days		1 year 5 months 12 days
Operating lease discount rate	4.67%		4.67%
Rent expense	$ 52,000	$ 52,000	$ 104,000	$ 104,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Stockholders' equity - Schedule of warrants or rights (Detail) - $ / shares	3 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Equity [Abstract]
Outstanding, beginning of period	107,095	145,421
Granted	559,162	0
Exercised	(281,581)	0
Cashless exercise	0	(38,326)
Outstanding, ending of period	384,676	107,095
Exercise price of class of warrants or rights outstanding	$ 10.50	$ 29.48
Granted	3.09	0
Exercised	3.10	0
Cashless exercise	0	82.50
Exercise price of class of warrants or rights outstanding and excercisable	$ 5.15	$ 10.50

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option - $ / shares	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options,Outstanding, beginning of period	69,717	70,161
Stock Options, Granted	525,546
Stock Options, Forfeited	(7,967)	(444)
Stock Options, Outstanding, end of period	587,296	69,717	70,161
Stock Options, Exercisable, end of period	35,473	43,273
Exercise price, beginning of period	$ 60.00	$ 60.42
Weighted-average Exercise Price, Granted	2.98
Weighted-average Exercise Price, Forfeited	153.78	69.32
Weighted-average Exercise Price, Exercise price, end of period	7.64	60.00	$ 60.42
Weighted-average Exercise Price, Exercisable, end of period	$ 48.18	$ 68.53
Weighted-average Remaining Contractual Term, Outstanding	9 years 2 months 12 days	2 years 7 months 24 days	2 years 10 months 20 days
Weighted-average Remaining Contractual Term, Exercisable	2 years 4 months 24 days	2 years 3 months 3 days

XML 59 R48.htm IDEA: XBRL DOCUMENT

Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based compensation expense	$ 82	$ 37	$ 120	$ 92
Research and development [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based compensation expense	6	17	15	0
General and administrative [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based compensation expense	$ 76	$ 20	$ 105	$ 92

XML 60 R49.htm IDEA: XBRL DOCUMENT

Stockholders' equity - Additional information (Detail) - USD ($)		6 Months Ended
	Oct. 06, 2020	Dec. 31, 2020
Unrecognised share based compensation expense		$ 1,393,000
IPO [Member]
Sale of Stock, Number of Shares Issued in Transaction	2,666,644
Sale of stock issue price per share	$ 3.10
Over-Allotment Option [Member]
Sale of Stock, Number of Shares Issued in Transaction	483,870
Sale of stock issue price per share	$ 3.10
Pre-funded warrants [Member]
Sale of Stock, Number of Shares Issued in Transaction	559,162	559,162
Sale of stock issue price per share	$ 3.09
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Number of Warranrs exercised		281,581

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ɶ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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 140 271 1 false 35 0 false 4 false false R1.htm 1001 - Document - Cover Page Sheet http://www.benitecbiopharmainc.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Balance Sheets Sheet http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 1007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Business Sheet http://www.benitecbiopharmainc.com/role/Business Business Notes 8 false false R9.htm 1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Going concern Sheet http://www.benitecbiopharmainc.com/role/GoingConcern Going concern Notes 10 false false R11.htm 1011 - Disclosure - Revenue Sheet http://www.benitecbiopharmainc.com/role/Revenue Revenue Notes 11 false false R12.htm 1012 - Disclosure - Cash and Cash equivalents Sheet http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents Cash and Cash equivalents Notes 12 false false R13.htm 1013 - Disclosure - Trade and other receivables Sheet http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables Trade and other receivables Notes 13 false false R14.htm 1014 - Disclosure - Other assets Sheet http://www.benitecbiopharmainc.com/role/OtherAssets Other assets Notes 14 false false R15.htm 1015 - Disclosure - Property and equipment, net Sheet http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet Property and equipment, net Notes 15 false false R16.htm 1016 - Disclosure - Trade and other payables Sheet http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables Trade and other payables Notes 16 false false R17.htm 1017 - Disclosure - Leases Sheet http://www.benitecbiopharmainc.com/role/Leases Leases Notes 17 false false R18.htm 1018 - Disclosure - Stockholders' equity Sheet http://www.benitecbiopharmainc.com/role/StockholdersEquity Stockholders' equity Notes 18 false false R19.htm 1019 - Disclosure - Income taxes Sheet http://www.benitecbiopharmainc.com/role/IncomeTaxes Income taxes Notes 19 false false R20.htm 1020 - Disclosure - Commitments and contingencies Sheet http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 20 false false R21.htm 1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 21 false false R22.htm 1022 - Disclosure - Business (Tables) Sheet http://www.benitecbiopharmainc.com/role/BusinessTables Business (Tables) Tables http://www.benitecbiopharmainc.com/role/Business 22 false false R23.htm 1023 - Disclosure - Revenue (Tables) Sheet http://www.benitecbiopharmainc.com/role/RevenueTables Revenue (Tables) Tables http://www.benitecbiopharmainc.com/role/Revenue 23 false false R24.htm 1024 - Disclosure - Cash and Cash equivalents (Tables) Sheet http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables Cash and Cash equivalents (Tables) Tables http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents 24 false false R25.htm 1025 - Disclosure - Trade and other receivables (Tables) Sheet http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesTables Trade and other receivables (Tables) Tables http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables 25 false false R26.htm 1026 - Disclosure - Other assets (Tables) Sheet http://www.benitecbiopharmainc.com/role/OtherAssetsTables Other assets (Tables) Tables http://www.benitecbiopharmainc.com/role/OtherAssets 26 false false R27.htm 1027 - Disclosure - Property and equipment, net (Tables) Sheet http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables Property and equipment, net (Tables) Tables http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet 27 false false R28.htm 1028 - Disclosure - Trade and other payables (Tables) Sheet http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables Trade and other payables (Tables) Tables http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables 28 false false R29.htm 1029 - Disclosure - Leases (Tables) Sheet http://www.benitecbiopharmainc.com/role/LeasesTables Leases (Tables) Tables http://www.benitecbiopharmainc.com/role/Leases 29 false false R30.htm 1030 - Disclosure - Stockholders' equity (Tables) Sheet http://www.benitecbiopharmainc.com/role/StockholdersEquityTables Stockholders' equity (Tables) Tables http://www.benitecbiopharmainc.com/role/StockholdersEquity 30 false false R31.htm 1031 - Disclosure - Business - Summary of entities in control (Detail) Sheet http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail Business - Summary of entities in control (Detail) Details 31 false false R32.htm 1032 - Disclosure - Business - Additional information (Detail) Sheet http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail Business - Additional information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail) Sheet http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail) Details 33 false false R34.htm 1034 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) Sheet http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) Details 34 false false R35.htm 1035 - Disclosure - Going concern - Additional information (Detail) Sheet http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail Going concern - Additional information (Detail) Details 35 false false R36.htm 1036 - Disclosure - Revenue - Summary of revenue from customers (Detail) Sheet http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail Revenue - Summary of revenue from customers (Detail) Details 36 false false R37.htm 1037 - Disclosure - Revenue - Summary of disaggregation of revenue (Detail) Sheet http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail Revenue - Summary of disaggregation of revenue (Detail) Details 37 false false R38.htm 1038 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail) Sheet http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail Cash and Cash equivalents - Summary of cash and cash equivalent (Detail) Details 38 false false R39.htm 1039 - Disclosure - Trade and other receivables - Summary of trade and other receivables (Detail) Sheet http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail Trade and other receivables - Summary of trade and other receivables (Detail) Details 39 false false R40.htm 1040 - Disclosure - Other assets - Summary of other assets (Detail) Sheet http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail Other assets - Summary of other assets (Detail) Details 40 false false R41.htm 1041 - Disclosure - Property and equipment, net - Summary of property and equipment net (Detail) Sheet http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail Property and equipment, net - Summary of property and equipment net (Detail) Details 41 false false R42.htm 1042 - Disclosure - Property and equipment, net - Additional information (Detail) Sheet http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail Property and equipment, net - Additional information (Detail) Details 42 false false R43.htm 1043 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail) Sheet http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail Trade and other payables- Summary of trade and other payables (Detail) Details 43 false false R44.htm 1044 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail) Sheet http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail Leases - Summary of maturities of the operating lease liabilities (Detail) Details 44 false false R45.htm 1045 - Disclosure - Leases - Additional information (Detail) Sheet http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail Leases - Additional information (Detail) Details 45 false false R46.htm 1046 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail) Sheet http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail Stockholders' equity - Schedule of warrants or rights (Detail) Details 46 false false R47.htm 1047 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail) Sheet http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail Stockholders' equity - Schedule of equity awards (Detail) Details 47 false false R48.htm 1048 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail) Sheet http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail Stockholders' equity - Summary of share-based compensation expense (Detail) Details 48 false false R49.htm 1049 - Disclosure - Stockholders' equity - Additional information (Detail) Sheet http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' equity - Additional information (Detail) Details 49 false false All Reports Book All Reports bntc-20201231.xml bntc-20201231.xsd bntc-20201231_cal.xml bntc-20201231_def.xml bntc-20201231_lab.xml bntc-20201231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 66 0001193125-21-033243-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-033243-xbrl.zip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�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end

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company